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Introduction 
In this chapter, the molecular changes relevant for bladder cancer development and 
progression will be outlined. Furthermore, the prognostic value of these changes will be 
discussed. Finally, the scope of this thesis is described. 
Bladder cancer 
Bladder cancer is the fifth most common cancer in the western male population; for 
women the incidence is about four times lower (173). In the Netherlands (15 million 
inhabitants) 3400 new cases of bladder cancer are diagnosed and approximately 1100 
patients die each year from this disease (38). Bladder cancer usually presents in the 
elderly (215) and is strongly correlated with smoking. Indeed, one-half of bladder 
carcinomas in men and one-third in women are attributable to smoking (85). Other 
agents associated with bladder cancer include the aromatic amines, aniline dyes, 
cyclophosphamide, and phenacetin (215). 
Transitional cell carcinoma (TCC) is the most common histologic type of bladder 
cancer, whereas squamous-cell carcinoma, adenocarcinoma, and undifferentiated 
carcinoma of the bladder account only for a minority of cases. TCC occurs in a wide 
spectrum of clinical and pathological appearances (204). 
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Figure 1. Different histological stages in TCC (36). 
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In Figure 1 a schematic drawing of the different histological stages of TCC is shown. 
About 80% of bladder tumors will present as superficial TCC, defined as tumor 
extension restricted to the mucosa (papillary shaped pTa tumors and flat carcinoma in 
situ (CIS)) or the lamina propria (pTl) of the bladder wall. Muscle-invasive (pT2-pT4) 
tumors account for 20% of bladder tumors, usually present de novo and are associated 
with a worse prognosis and a propensity to metastasize. Most patients with superficial 
bladder cancer have a good prognosis (173,226). Although 30 to 90% of the tumors will 
recur depending on stage, grade, multifocality and treatment modality, only 10-25% 
become invasive or metastasize during the course of the disease (74,101,102). The 
highest recurrence and progression rates are observed in pTlG3 tumors while pTaG3 
and pTlG2 tumors show similar rates (108). 
A significant problem in the management of patients with superficial TCC is the 
identification of those patients who are at risk for progression to invasive disease, so that 
an early change in treatment strategy (conservative to radical) can be made to potentially 
prevent progression. For invasive bladder cancer, the identification of the metastatic 
potential of a given tumor is very important because 50% of patients even if treated with 
radical cystectomy will die of systemic disease. To address these problems many 
investigators have tried to identify markers associated with the progression from 
superficial to invasive or metastatic disease. The recent advances in the molecular 
approach to tumor biology have revolutionized our knowledge of cancer genetics. 
Hopefully, a better understanding of the molecular genetic changes involved in bladder 
cancer progression will provide diagnostic and prognostic information. 
Molecular basis of bladder cancer 
Genetic studies 
In general, abnormal DNA content (aneuploidy) is recognized as a marker of 
malignancy. In bladder cancer, the overall incidence of aneuploidy rises with increasing 
stage and grade (29,40,79,219,248). Several techniques can be applied to study genetic 
aberrations during tumor development and progression. DNA content analysis is not 
able to discriminate between small differences in DNA content, and therefore not 
suitable to identify specific genetic alterations. Cytogenetic studies revealed an 
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association between more specific chromosomal changes and carcinogenesis and disease 
progression. 
Conventional karyotype analyses have shown non random chromosomal changes in 
bladder cancer involving chromosomes 1, 5, 7, 9 and 11 (3,12,70,71,178,202,231). 
Gibas et al. (71) designated deletion from chromosome 11 as a secondary event in 
bladder cancer development associated with muscle invasion. Hopman and coworkers 
performed interphase cytogenetics using centromere-associated probes to study 
numerical and structural chromosomal changes in non mitotic cells (88,89,90,168). 
These studies showed chromosome 9 to be under represented as compared to other 
chromosomes in low stage/low grade TCC, suggesting the loss of this chromosome as 
one of the primary events in the development of TCC. A new in situ hybridization 
technique (ISH), comparative genomic hybridization (CGH) allows screening of a tumor 
genome for chromosomal imbalances (97). The use of CGH to identify DNA alterations 
in a limited number of TCCs revealed besides known chromosomal losses, distinct 
amplifications on lp22, lq31, 3q24-q26, 8q21, 10pl3-14, 12ql3-15, 13q21-q34, 17q22-
23, 18pll and 22ql 1-13 (98,239). 
The technique of Restriction Fragment Length Polymorphism (RFLP) allows an even 
more detailed analysis of chromosomal changes. The most important allelic losses have 
been observed on chromosomes 3p (77), 4p (105), 8p (103), 9q and 9p (77,104,221), 
l ip (51,77,221), 13q (77); 17p (77,159,221) and 18q (17,105). Loss of heterozygosity 
(LOH) of chromosomes 3p, 8p, l ip, 13q, 17p and 18q was associated with high stage 
and high grade tumors. Habuchi and coworkers (77) showed that the loss of 
chromosome 9q was equally observed in low stage/low grade and high stage/high grade 
tumors. Furthermore, they found that although the loss of l ip was more frequently 
associated with invasive phenotype, the LOH of l ip was detected in 35% of non-
invasive tumors. Therefore they concluded that the loss of 1 lp might occur at an earlier 
stage before the loss of 17p, 13q, and 3p in tumor progression. The most important 
chromosomal changes found in bladder cancer so far are summarized in Figure 2. 
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Putative molecular pathways in bladder cancer progression 
Figure 2 also shows the two molecular pathways thought to be involved in bladder 
cancer progression. Initially, the loss of chromosome 9 was shown to be an early event 
in bladder cancer progression, whereas the loss of chromosome 17p occurred at a later 
stage. The tumor suppressor gene located on 17pl3.1 is p53 (11) and mutations in the 
p53 gene were associated with high stage tumors (199). It was suggested that loss of 
chromosome 9 may cause proliferative behavior and that p53 mutations were necessary 
to initiate progression to invasive disease. However, it has recently been shown that in 
65% of CIS, the p53 gene is mutated, whereas chromosome 9 deletions occur 
significantly less frequent than in invasive tumors (146,207). These results suggest the 
existence of a second molecular progression pathway to invasive disease, whereby the 
p53 mutation is the initial event and chromosome 9 loss occurs later. 
Figure 2. The two putative molecular pathways in bladder cancer progression. 
Candidate oncogenes and tumor suppressor genes 
Many of the regions involved in allelic loss are likely to harbor tumor suppressor genes, 
whereas the chromosomal amplifications could indicate the presence of prolo-
oncogenes. Table 1 summarizes the chromosomal regions that may harbor genes 
involved in bladder cancer development or progression. The gene for the retinoic acid 
receptor is located on chromosome 3p and it is of interest since the loss of this receptor 
is correlated with a poor prognosis in bladder cancer (37,138). The von Hippel-Lindau 
(VI IL) disease tumor suppressor gene is also located on chromosome 3p but its 
relevance for bladder cancer is not yet determined (113). DNA polymerase ß is an 
interesting candidate gene which maps within the region of deletion on 8p21-8ql 1.2 that 
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might have an effect on the mutation rate (105). At least two tumor suppressor genes are 
likely to be mapped on chromosome 9 (100,161,175). Region 9p2I-22 is of particular 
interest because two studies independently reported homozygous deletions in this region 
(23,41). The CDKN2 (MTS1) gene is located at 9p21, its product, ρ 16, inhibits the 
cyclinD/cdk4 complex that phosphorylates pRB, thus negatively regulating cell cycle 
progression (193). The deleted area on chromosome lip contains the ras oncogene 
(165), the two Wilms' tumor suppressor loci (WT1 and WT2, at Hpl3 and 11 ρ 15, 
respectively) (25,107) and the CAT locus, that is thought to be involved in DNA repair 
processes (197). The retinoblastoma gene, the first identified tumor suppressor gene, is 
the candidate gene on 13q 14 (206). As addressed earlier chromosome 17p harbors the 
tumor suppressor gene p53. The DCC gene (18q21), known to be involved in colorectal 
cancer (52), might be the target of deletions in a subset of bladder tumors. 
Table 1 . Chromosomal deletions in bladder cancer and candidate oncogenes and tumor 
suppressor genes. 
Locus Candidate gene 
3p retinole acid receptor, VHL 
8p21-8q11.2 DNA polymerase ß 
9p21-22 CDKN2 
l i p Η-ras; WT1 (11p13); WT2 (11p15); CAT locus 
13q14 RB 
1 7 p l 3 . 1 p53 
18q21 DCC 
The exact biological role of these chromosomal aberrations and the genes involved is 
subject for on-going investigations and once these genes are identified, a more complete 
view of the genetic events that determine progression will be possible. 
Differential gene expression 
Another approach in the search for new molecular markers with prognostic value is to 
compare different stages of progression at the level of gene expression by means of 
differential or substraction hybridization analysis of cDNA libraries. These methods are 
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based on comparison of steady state mRNA populations. A drawback of these 
techniques is that genes that are aberrantly expressed (i.e. different size of transcript) can 
not be identified, unless the level of steady state mRNA has changed. Differences in 
post-translational regulation cannot be identified using this approach. However, the 
advantages of differential/substraction hybridization analyses are, that relevant but 
unknown genes can be isolated. Moreover, genes that are either upregulated (e.g. 
oncogenes) or down modulated (e.g. tumor suppressor genes) can be identified. The 
cDNA clones identified can be routinely characterized by DNA sequence analysis and 
comparison of the resulting DNA sequence with nucleotide sequence data bases. If the 
isolated cDNA clone is of interest it can be immediately evaluated for its use in 
diagnosis by RNA in situ hybridization analysis (211). The selection of the method for 
comparing mRNA populations depends on the relative abundance of the mRNA 
population of interest. To study high and low abundance transcripts (>0.01%), the 
differential hybridization analysis is a valid approach (180,189). The identification of 
very low abundance (<0.01%) differentially expressed genes, requires a more 
sophisticated approach, i.e. substraction hybridization analysis which is based on the 
substraction of common mRNAs from a given population, thus leaving unique mRNAs 
(at very low levels, 0.001%) (218). Both differential and substraction hybridization are 
technically difficult and require relative large amounts of approx. 5 \іщ poly-A+ RNA. A 
recently developed alternative approach, named mRNA differential display offers the 
important advantages that much less mRNA (approx. 10 ng/reaction) is required. 
Furthermore, it is quicker and technically simpler (120,121,122). The most essential part 
of these three "gene-hunting" techniques is the choice of the mRNA populations that are 
compared which should be homogeneous and well characterized. At present the above 
mentioned techniques have succeeded in isolating only a small number of important 
genes, i.e., NM23 (208), stromelysin-3 (8), EMS1 (191) and WAF-1 (45), which were 
all identified in very precisely defined populations. 
In the following paragraphs the value of the most relevant known molecular prognostic 
markers for bladder cancer will be discussed. 
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Molecular prognostic factors 
DNA ploidy 
By DNA flow cytometry or image cytometry insight can be obtained in the extent of 
genetic damage. In a few studies the biological significance of aneuploidy in tumor 
progression has been addressed. It has been hypothesized that tumor cells first acquire a 
tetraploid status, whereafter cells can evolve by chromosome loss without lethal effect 
(42,69). Thus, more aggressive clones could emerge at a higher rate in these tumors than 
in diploid tumors. Aneuploidy in bladder tumors has been extensively studied and 
correlates with a high propensity to progress to invasion and metastasis as well as with 
poor survival (14,106). In muscle invasive operable bladder cancer, DNA ploidy does 
not represent a prognostic parameter (58). For superficial bladder cancer (Та/Tl) the 2c 
deviation index appeared to have significant predictive value for survival (15,190) 
However, the DNA content may be a differential prognostic marker only for grade 2 
tumors, since most grade 1 tumors are diploid and most grade 3 tumors are aneuploid. 
Epidermal Growth Factor Receptor 
The interest in studying Epidermal Growth Factor (EGF) and its receptor (EGFR) was 
based on the finding of high EGF (urogastron) levels in urine. Messing et al. reported in 
1984 that growth and division of certain TCC cell lines responded to EGF (140). Several 
investigators have studied the epidermal growth factor receptor (EGFR), the product of 
c-erbB-1 (located on chromosome 7), and found a significant correlation between EGFR 
overexpression and both grade and stage (13,141,153,174). The correlation between 
EGFR positivity and clinical outcome was studied immunohistochemically in 101 
bladder tumors (125,154,155). EGFR overexpression appeared to be a significant 
prognostic factor for the whole group studied. The difference in survival between 
EGFR-positive tumor and EGFR-negative tumor bearing patients was not significant 
when the data from patients with muscle invasive disease were analyzed separately. 
However, in patients with superficial TCC (pTa, pTl), EGFR overexpression is 
correlated with recurrence rate, time to recurrence and tumor progression. 
EGFR gene amplification has been studied by Southern blot analysis but was found in 
only one out of 31 bladder tumors (13). When the polymerase chain reaction was used to 
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assess EGFR amplification in carcinoma cells from bladder washings, an amplification 
in 2 out of 47 patients was observed (131). A more recent study showed the same rate of 
EGFR gene amplification (5 out of 107 tumors) (187). Apparently, EGFR gene 
amplification is not a predominant mechanism for EGFR overexpression. 
EGFR expression can be induced by overexpression of the Η-ras gene. This was found 
to occur both at the protein and mRNA levels and analysis of EGFR promotor/enhancer 
sequences has revealed a putative AP-1 site which may possibly serve as a ras 
responsive element (212). These results suggest a role for overexpression of H-ras, 
whether wild type or mutant, in upregulating the EGFR. Mutated Η-ras in bladder 
cancer has been reported at various frequencies ranging from 6%-44% in different 
studies, but no correlation with grade or stage was observed (20,35,57,104,116). This 
range in mutation frequencies could be caused by the use of different detection methods 
and variable tumor specimens. The exact role of Η-ras in bladder cancer remains to be 
elucidated. 
In conclusion, overexpression of EGFR might be useful as a prognostic marker in the 
group of superficial bladder tumors. 
C-erbB-2 
C-erbB-2 is a human proto-oncogene located on chromosome 17q21 encoding a 
transmembrane growth factor receptor with significant sequence homology to the EGFR 
(252). Different studies showed varying rates of c-erbB-2 gene amplification ranging 
from 8%-46%. C-erbB-2 protein overexpression was shown to be more frequent than the 
gene amplifications (32,186,256). Hence, for c-erbB-2 overexpression, gene 
amplification also does not seem to be the predominant mechanism. Moreover, 
Underwood and coworkers (227) concluded that c-erbB-2 gene amplification was of no 
value as an independent marker for the prediction of disease recurrence or progression. 
Sato et al. (185) showed c-erbB-2 protein expression to be correlated with tumor grade 
and survival. Multivariate analysis showed that c-erbB-2 expression was a prognostic 
factor independent of grade and stage of the tumors. In contrast to the findings of other 
recent immunohistochemical studies (114,125,227). Although the study of Lipponen 
(125) showed a correlation between c-erbB-2 expression, grade, DNA aneuploidy, high 
S-phase fraction and decreased survival, no additional significant prognostic value over 
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already established prognostic parameters in TCC was found. In the other two studies no 
significant correlation with either grade, stage or survival was observed. 
At present it appears that c-erbB-2 gene amplification and protein overexpression have 
no additional predictive value for disease recurrence or progression. The disparity 
between the different immunohistochemical studies emphasizes the need for further 
detailed investigation. 
The Retinoblastoma gene 
Another tumor suppressor gene potentially involved in bladder cancer is the 
Retinoblastoma (RB) gene located on 13ql4. Restoring the wild-type RB function in a 
RB-negative cell line (HTB9) resulted in complete suppression of growth in son agar 
and decreased tumorigenicity in nude mice, suggesting a key role for the RB gene in 
bladder cancer (209). The RB gene encodes a nuclear phosphoprotein and several 
investigators have hypothesized that it functions as a cell cycle control protein (72,115, 
244). More recently, it has been suggested that pRB functions downstream of p53 in the 
same regulatory pathway. HPV proteins E6 that targets p53 for destruction and E7 that 
binds to pRB, undermine the p53-pRB-dependent damage checkpoint (39,201). p53 
influences the activity of cyclin-dependent kinases that phosphorylate pRB, via p21 
production (45). High levels of p21 inhibit cyclinE-Cdk2, which usually phosphorylates 
pRB in Gl/S of the cell cycle, thereby resulting in hypo-phosphorylated pRB. This form 
of pRB blocks the transcription of genes required for subsequent stages of the cell cycle 
and arrests the cell cycle. 
Loss of RB function at the protein level occurs in approximately one-third of human 
bladder cell lines (92). Gross structural deletions of the RB gene as well as point 
mutations have been documented in many of these cell lines (91,92). More recently, loss 
of RB protein expression and deletions at the RB locus have been identified in primary 
bladder cancers, and it appeared that altered RB expression is correlated with high grade 
and high stage tumors (22,33,68,73,95,128,130,251). A strong correlation was found 
between LOH at the RB locus and the absence of normal RB protein expression (251). 
Rb gene mutations have been shown to occur in both low grade superficial as in high 
grade invasive bladder cancers (145). Two immunohistochemical studies have shown 
that a decreased expression of the RB protein is associated with a more aggressive 
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biological behavior (33,130). Decreased Rb expression correlated with shortened 
survival in the group with invasive tumors. Based on current knowledge it can be 
concluded that altered RB protein expression may be a prognostic marker in patients 
with invasive bladder cancer. 
E-Cadherin 
To metastasize, cancer cells must be released into the blood or lymphatic stream. 
Decreased intercellular adhesiveness favors detachment of tumor cells and may play a 
role in the early steps of the metastatic process. Although cell-cell adhesion is complex 
involving at least four families of adhesion molecules (integrin, immunoglobulin, 
selectin, and Cadherin), several lines of evidence indicate that the Ca -dependent, E-
cadherin-mediated adhesiveness is critically important for epithelial integrity (210). 
Modulation of E-cadherin function of several tumor cell lines either by blocking 
antibodies or by transfection experiments revealed an invasion suppressor role for E-
cadherin-mediated cell-cell adhesion in vitro (10,63,235). The correlation between E-
cadherin expression and in vitro invasiveness has been tested for 3 bladder cell lines. 
The RT4 and RT112 cell lines express E-cadherin and are not invasive, whereas the 
EJ24 cell line does not express E-cadherin and is invasive (63). E-cadherin expression 
has been analyzed in 49 bladder tumors with anti-E-cadherin monoclonal antibodies 
(18). In this immunohistochemical study decreased E-cadherin expression correlated 
with both increased grade and stage whereas abnormal E-cadherin expression correlated 
with shorter survival for the whole group studied as well as for the group with invasive 
tumors. No conclusions can be drawn for the patients with superficial TCC. These data 
were recently confirmed by Otto et al. (162) who also observed a concomitant 
association between increased overexpression of the autocrine motility factor and 
progression of disease. In conclusion, E-cadherin seems to have potential as a prognostic 
marker although its precise clinical relevance has to be assessed in larger clinical trials. 
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Potential prognostic factors 
Besides the most relevant prognostic parameters, there is an additional panel of 
molecular factors with potential prognostic relevance but only the most important 
parameters will be discussed. 
Scatter factor (SF) has been shown to be overproduced by bladder carcinomas (96) and 
is involved in invasion and angiogenesis. Both are characteristics of biologically 
aggressive tumors suggesting that the accumulation of SF within tumors might promote 
progression to a more malignant phenotype. Its exact clinical relevance remains to be 
determined. Fradet and coworkers raised monoclonal antibodies against tumor-associa-
ted antigens (59,60,61). The most relevant ones are the tumor-associated antigens M344 
and T138. M344 is predominantly expressed on superficial TCC and its expression 
decreases with increasing grade of the tumors (62). Preliminary data suggest that M344 
positive tumors rarely progress. T138 was found to have an independent significant 
prognostic value for bladder cancer (174). Larger clinical studies, in which also the 
separate groups of superficial and invasive tumors are studied, are necessary to reveal 
the exact clinical usefulness of T138. 
Altered expression of MDM2 is reported in bladder cancer (78,119) and overexpression 
is associated with low grade, low stage bladder tumors and has been implicated in the 
progression of bladder cancer. Whether MDM2 overexpression represents an alternative 
to p53 mutation in inactivating the p53 regulatory pathway is still unclear. 
The p53 tumor suppressor gene 
The p53 gene 
The most extensively studied tumor suppressor gene is p53, often referred to as "the 
guardian of the genome" (111). Since the main part of the present thesis concerns the 
value of p53 as a prognostic marker in bladder cancer, p53 will be discussed more 
extensively. 
The p53 gene is located on chromosome 17p 13.1 (11) and it is mutated in over half of 
all human tumors (87). Frequently one of the two alleles is lost and the other is mutated 
(6,87). Most mutations are found in four conserved domains (II: aa 117-142; III: aa 171-
181; III: aa 234-258; IV: aa 270-286), located in the DNA binding domain of the p53 
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protein (205). The protein encoded by the p53 gene is a 53-kd nuclear phosphoprotein 
consisting of a transactivation-, a DNA binding- and an oligomerization domain (Figure 
3). 
Trans activation 
dsDNA PK & 
CKI 
NH2 
100 
Sequence-specific DNA binding 
200 
Oligomerization 
300 
111 0 0 ®-
TBP, mdm-2 E1b E6 \ / 
SV40 Tag 
NLS 
-θι 
COOH 
393 
Figure 3. Structural domains of human p53. Boxes II to V represent the conserved 
regions containing the frequent sites of mutation. Above the p53 sequence the different 
domains of p53 activity and the positions of defined phosphorylation are indicated. Below 
the p53 sequence, the main nuclear localization signal (NLS) and the interaction of various 
factors with p53 are shown. Abbreviations: dsDNA-PK, double-stranded protein kinase; 
CKI, casein kinase I; cdc-2, p34 0 d c 2kinase; CKII, casein kinase II; TBP, TATA binding 
protein; mdm-2, murine double minute-2; E 1b, adenovirus 5 E1b protein; E6, human 
papilloma virus E6 protein, SV40 Tag, simian virus 40 large Τ antigen; NLS, nuclear 
localization signal (adapted from: Harris et al. (84); Prives et al. (170)). 
Transcriptional regulation by p53 
The tumor suppressor protein p53 plays a role as a transcriptional regulator (49,99,129, 
166,238,253) and is involved in the control of the cell cycle at Gl to S phase transition 
(54,134). When DNA is damaged, p53 can delay the progression through the cell cycle 
allowing DNA repair (134) or can initiate programmed cell death (apoptosis) (132). It 
should be stressed that p53 is more involved in regulating and controlling the cell cycle, 
than in playing a direct mechanistic role in cell cycle progression. Studies using knock­
out mice have demonstrated that functional p53 is not essential for mitotic or meiotic 
cell cycles, but the high incidence of tumor development in p53-null mice (43) strongly 
suggests that p53 provides an important checkpoint that prevents aberrant growth, 
division and neoplastic transformation. Loss of wild type p53 function results in an 
altered Gl-S cell cycle checkpoint which can lead to replication of incorrect DNA, 
resulting in genetic instability (129,253). 
19 
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p53 acts both through transcriptional suppression and transcriptional activation. The p53 
protein interacts with the transcription factors Taf
n
40 and Tafn60 (216) and possibly also 
with the TATA binding protein (TBP) (28,195,220). These interactions are thought to 
contribute to the ability of p53 to repress general transcription. p53 can activate 
transcription by binding to repeats of the DNA consensus site PG (44). Viral oncogenes 
that overcome p53-mediated growth suppression abrogate its ability to transactivate 
(142). A few targets of p53 transcriptional activation have been identified that might 
account for the Gl arrest in response to DNA damage (Figure 4). 
Гвад ГвсІ2~) ( в а ж Г в а ж ) 
G, - * . S DNA EXCISION REPAIR 
REPLICATION 
APOPTOSIS 
Figure 4. The p53 mediated response to DNA damage (177). 
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The p53 mediated responses to DNA damage 
DNA repair 
WAF-1 (wild-type p53 activated fragment), also known as CIP1 (83) and Sdi (156), was 
isolated by substractive hybridization screening from cells overexpressing p53 (45). The 
protein p21 encoded by WAF-1 is an inhibitor of Gl cyclin dependent kinases and 
complexes with cyclin, Cdk and PCNA (proliferating cell nuclear antigen) in normal 
cycling cells (250). The p21 protein is known to interact directly with PCNA thereby 
blocking its replication, but not its repair activity (118,198,240,242). Although 
upregulation of p21 by p53 appears to be the most important mediator of p53 mediated 
growth arrest, other genes that are transcriptionally activated by p53 may also play a role 
in DNA damage-dependent cell cycle arrest. 
For example, cyclin GÌ, a gene, whose expression is induced by wild-type p53 (157), 
might be a candidate although its exact role in cell cycle arrest or apoptosis is not clear 
(21). The excision repair ERCC3 gene may also be transcriptionally induced by p53 
(241). Smith and coworkers showed that GADD45 (growth arrest and DNA damage 
gene) which is also upregulated by p53, probably serves as a link between the p53-
dependent cell cycle checkpoint and DNA repair (203) (Figure 4). GADD45 can interact 
directly with the essential replication factor PCNA (203), thereby blocking DNA 
replication and possibly enhances nucleotide excision repair of damaged DNA. 
Apoptosis 
The responses mentioned above presumably favor enhanced survival. However, in some 
situations, p53 activates a suicide pathway (apoptosis) following DNA damage. 
Recently, Miyashita and Reed (147) suggested a mechanism by which p53 might induce 
apoptosis. Bax and Bcl-2 are homologous proteins that have opposing effects on 
apoptosis (Figure 4). Bcl-2, the product of a proto-oncogene, protects the cell from 
apoptosis, while Bax acts as an apoptotic signal (158). The upregulation of p53 in some 
cell types is concomitant with the down-regulation of Bcl-2, and the upregulation of 
Bax. The induction of the Bax protein increases the concentration of Bax:Bax 
homodimers and Bax:Bcl-2 heterodimers in the cell, thereby potentiating apoptosis 
under certain circumstances (158). Recent evidence indicates that a functional p53 
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pathway is required for efficient cell kill by chemotherapeutic agents (56,133), although 
conflicting findings have also been reported (16,65). 
The p53 protein controls the maintenance of DNA integrity by the mechanisms 
mentioned above. In addition to mutation, loss of wild type p53 function can be the 
result of complexation with viral oncoproteins, e.g., simian virus 40 (SV40) Large Τ 
antigen (110,124), adenovirus 5 Elb (184) and E6 protein of human Papillomavirus 16 
and 18 (243). The cellular oncoprotein, mdm2 also interacts directly with p53 and 
functionally inactivates it (148). 
Prognostic value of p53 
The p53 tumor suppressor gene can be studied directly by analyzing p53 gene mutations 
using e.g. Single Strand Conformation Polymorphism (SSCP) or direct sequencing. The 
occurrence of p53 mutations can lead to conformational changes of the p53 protein, 
resulting in a prolonged half-life and subsequently, in accumulation of the protein (55). 
The extended half-life of the protein is the basis for immunohistochemical detection of 
p53. Despite the good concordance between p53 mutation and p53 overexpression, 
discrepancies are observed in a substantial number of tumors. (34,46,214; this thesis). 
A number of studies have investigated p53 genetic alterations in bladder cancer. The 
loss of heterozygosity of chromosome 17p is associated with high grade and high stage 
bladder carcinomas (159). By means of subcloning and sequencing of exon 5 through 9 
of the p53 gene, it has been shown that 17p allelic loss is strongly associated with p53 
mutation in 9 out of 10 cases and that p53 mutation is associated with high stage tumors 
(199). The correlation between p53 mutations and stage as well as grade was confirmed 
in four other studies using PCR-SSCP (64,207,245; this thesis). Analysis of p53 
mutations in carcinoma in situ showed a high prevalence of 65% of p53 mutations 
similar to that seen in invasive bladder cancer (146,207) (see Figure 2). 
The relatively high frequency of p53 mutations in T2-T4 tumors compared to Tl tumors 
suggest their involvement in the progression of Tl tumors to invasive disease (207). 
However, the exact point at which p53 mutations occur during tumor progression from 
Ta to Τ1 and T2-T4 tumors is still unclear. p53 mutations were reported to have 
prognostic significance for bladder cancer (225; this thesis), although it offered no 
additional prognostic value over stage for invasive bladder cancer (T2-T4) (this thesis). 
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The exact prognostic value of p53 mutations for superficial bladder cancer remains to be 
determined. 
Overexpression of the p53 protein has been reported to have a clear prognostic 
significance for superficial bladder cancer (47,181,182,194), although conflicting data 
were also reported (66,125). Differences in antibody, methodology, treatment of the 
patients and the scoring systems used might explain these differences. The prognostic 
value of p53 overexpression is also ambiguous for invasive tumors (47,125,183; this 
thesis). Apparently, as long as the tumors are confined to the bladder (pT<3A, confined 
to the detrusor muscle), p53 immunohistochemistry has prognostic value. With more 
extensive disease, p53 alterations have no additional prognostic value. 
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Scope of this thesis 
In this thesis two approaches are used to investigate the predictive value of molecular 
markers for bladder cancer progression 
First, the prognostic value of a known gene, the tumor suppressor gene p53, was studied 
Alterations of p53 can be studied by various methods In chapter 2, the direct detection 
of mutations in the p53 gene by PCR-SSCP and the immunohistochemical detection of 
p53 protein overexpression were compared to assess their usefulness To evaluate the 
prognostic value of p53 alterations in bladder cancer, we studied the association of both 
p53 overexpression (Chapter 2) and p53 mutations (Chapter 3) with grade, stage and 
survival Furthermore, the association of p53 mutations with frequency of allelic loss as 
a putative indicator of genetic instability, was investigated To assess the value of p53 
mutations (PCR-SSCP) in predicting the progression of superficial TCC, consecutive 
bladder washings from high risk superficial TCC patients (indicated by quantitative 
karyometnc analysis) were examined (Chapter 4) To determine the actual value of 
bladder washing specimens to assess the p53 status of histological specimens we 
analyzed the bladder washings and their synchronous tumors for the presence of p53 
mutations (Chapter 5) 
As a second approach we used differential hybridization analysis to identify new 
molecular prognostic markers We used a rat bladder tumor model system (RBT), in 
which the different stages of tumor progression are represented In the differential 
hybridization analysis the mRNA populations of low and high metastatic lines were 
compared (Chapter 6) 
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Chapter 2 
Comparison of p53 protein overexpression with 
p53 mutation in bladder cancer: 
Clinical and biological aspects. 
Jacqueline A M Vet', Pierre Paul Bnnguier', H Ewout Schaafsma , J Alfred Witjes , Frans 
M J Debruyne and Jack A Schalken' 
Abstract 
BACKGROUND Alterations of the tumor suppressor gene p53 are known to occur in bladder 
cancer Although p53 overexpression is associated with mutation of the p53 gene, a substantial 
discrepancy between molecular genetic alteration in p53 and overexpression of the protein has 
been found 
EXPERIMENTAL DESIGN Tumor specimens of 39 bladder cancer patients were 
immunohislochemically analyzed for p53 overexpression, and the results were compared with 
the presence of a mutation as assessed by Single Strand Conformation Polymorphism (SSCP) 
and direct sequencing Both clinical and biologic aspects were studied 
RESULTS A significant correlation between p53 overexpression and poor survival in the 
whole group studied was found (p<0 01) No association between p53 overexpression and 
decreased survival was found for invasive tumors in contrast with other studies Differences in 
treatment of the patients and different antibodies and scoring systems used might explain these 
differences In our study, the Kaplan Meier curves showed the same result for p53 
overexpression and p53 mutation when the whole group and the invasive tumors were studied 
However, in the group of superficial tumors, which was unfortunately too small for statistical 
analysis, we found p53 overexpression in three tumors while no p53 mutations were found 
A good concordance between p53 mutation and p53 overexpression was found (p<0 02) 
However, two out of eight tumors with an SSCP proven p53 mutation showed no p53 
immunoreactivity, probably as a result of loss of the nuclear localization signal Twenty three 
percent (7/31) of the tumors showed p53 overexpression without any sign of a mutation 
CONCLUSION Our results indicate that, despite a good concordance between p53 mutation 
and p53 overexpression, there is no direct causal relationship between mutation and protein 
accumulation Apparently other events than mutation can trigger p53 stability 
Department of Urology , University Hospital Nijmegen and the Department of Pathology , 
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands This study was supported by the 
Dutch cancer foundation, NUKC9102 (J A M V ) and FUSEX (Ρ Ρ В ) Published in Lab Invest 
73(6) 837-843 1995 
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Introduction 
The tumor suppressor gene p53 is located on chromosome 17p 13.1 and encodes a 53 kD 
nuclear phosphoprotein with specific DNA binding properties. Chromosomal losses of 
17pl3 occur during tumor progression in a variety of human tumors (87). In bladder 
cancer, loss of 17pl3 is associated with high grade tumors and invasive disease 
(159,169). In accordance with the classic tumor suppressor theory, the loss of 
heterozygosity (LOH) of 17pl3 is often accompanied by a mutation of the remaining 
allele (6). In bladder cancer, p53 mutations correlate with grade and stage (64,199,233) 
and probably play a role in the progression of this disease. 
Wild-type p53 acts as a cell cycle control protein at the level of Gl to S phase transition 
(99). If DNA damage occurs, p53 levels rise and block cells in the Gl phase. The DNA 
damage can subsequently be eliminated either by DNA repair or by initiation of 
apoptosis (132). The up-regulation by p53 of p21, an inhibitor of Gl су cl in-dependent 
kinases, appears to be responsible for p53 mediated growth arrest (94). Recently, Smith 
et al. showed that Gadd45 which is upregulated by p53, probably serves as a link 
between the p53-dependent cell cycle checkpoint and DNA repair (203). p53 seems to 
function through modulation of transcriptional activity, enhancing the expression of 
genes containing p53-binding sites and interacting with a variety of transcription factors 
to inhibit the expression of other genes (166,254). Cells that lose this wild type p53 
function fail to show growth arrest if DNA damage occurs which can lead to replication 
of incorrect DNA, resulting in genetic instability (129,253). 
In addition to mutation, loss of wild type p53 function can be the result of complexing 
with viral oncoproteins, e.g., simian virus 40 (SV 40) large Τ Ag (110,124), adenovirus 
5 Elb protein (184) and E6 protein of human Papillomavirus 16 and 18 (243). The 
cellular oncoprotein mdm2 also interacts directly with p53 and functionally inactivates it 
(148). 
The occurrence of p53 mutations leads to conformational changes of the protein, 
resulting in a prolonged half-life and subsequently in accumulation of the protein (55). 
The extended half-life of the protein is the basis for immunohistochemical detection of 
p53. Although there is a good concordance between p53 overexpression and mutation of 
the p53 gene, several studies have shown a considerable discrepancy beUveen molecular 
genetic alteration in p53 and overexpression of the protein (26,81,137,249). 
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In this study we compared the immunohistochemical detection of p53 overexpression 
with p53 mutation as assessed by Single Strand Conformation Polymorphism (SSCP). 
Materials and methods 
Tumor specimens 
Twenty-three snap frozen, superficial bladder carcinomas (pTa-pTl) and 24 muscle-
invasive bladder carcinomas (pT>2) obtained from 45 patients were used for SSCP 
analysis, as described previously (233). The transitional cell carcinomas were classified 
according to the World Health Organisation criteria (149). For immunohistochemistry 
the same specimens were investigated with the exception of 2 superficial and 2 invasive 
carcinomas that could not be analyzed because of poor quality of the frozen tissue. 
Moreover, the two squamous cell carcinomas were removed from this study because of 
their different pathologic background. The clinical and pathologic data are shown in 
Table 1. Genomic DNA was extracted from step-sectioned tumors (>70% tumor cells) 
using a method described by Miller and coworkers (144). 
Immunohistochemistry 
Cryostat sections (5 цт) were dried overnight. Tissue sections were fixed in acetone for 
10 minutes and then incubated overnight at 4°C with the mouse mAb DO-7 
(Novocastra, Newcastle upon Tyne, UK) at a dilution of 1:100. This Ab recognizes both 
wild-type and mutant p53. Sections were subsequently incubated for 30 minutes with 
biotinylated sheep anti-mouse lg antibody (1:200, Amersham, Buckinghamshire, UK) 
and then incubated for 30 minutes with streptavidin biotinylated-horseradish peroxidase 
complex (1:100, Amersham). After washing with PBS, 3,3'- Diaminobenzidine (Sigma 
Chemical Company, St. Louis, MO, USA) was used as a chromogen and hematoxylin 
for counterstain. 
Analysis of the immunohistochemical results was performed by two investigators (J.V., 
P.P.B). The pattern of p53 nuclear overexpression was classified in four categories by 
estimating the percentage of stained tumor cells: - , no cells positive; +, 1 to 10% 
positive tumor cells; ++, 10 to 50% positive tumor cells and +++, > 50% positive tumor 
cells. Cytoplasmic staining was not scored. 
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PCR-SSCP 
PCR-SSCP analysis (160) was performed to investigate p53 mutations in exons 5 to 8 . 
The intron primers for amplification of exons 5 to 8 were: 5S (5'-tca-ctt-gtg-ccc-tga-ctt-
3'), 5AS (5'-gag-gaa-tca-gag-gcc-tgg-3'), 6S (5'-gag-acg-aca-ggg-ctg-gtt-3'), 6AS (5'-
gag-acc-cag-ttg-caa-acc-3'), 7S (5'-cca-agg-cgc-act-ggc-ctc-3'), 7AS (5'-gag-gca-agc-
aga-ggc-tgg-3'), 8S (5'-cct-tac-tgc-ctc-ttg-ctt-c-3'), 8AS (5'-tga-atc-tga-ggc-ata-act-3'). 
Genomic DNA (250 ng) was subjected to 35 cycles of PCR (95, 57 and 72°C for 0.5, 2 
and 1.3 minutes, respectively). Exons 5, 6 and 8 were amplified in 50 μΙ containing: 50 
mM KCl, 10 mM Tris-HCl (pH 8.8), 1.75 mM MgCl2, 250 μΜ deoxynucleotide 
triphosphates, 10 pmol of each 5'end-labeled primer and 1.5 U of Taq polymerase 
(Perkin Elmer/Cetus, Norwalk, Connecticut, USA). Exon 7 was amplified in the same 
buffer containing 1.5 mM MgCl2. 
Five microliters of the PCR product was diluted in 15 μΐ loading buffer (96% 
formamide, 20 mM EDTA, 0.05% bromophenol blue and xylene cyanol), boiled for 3 
minutes and then quenched (10 minutes) on ice before loading (2 μΙ/lane). Each sample 
was applied to a 5% Polyacrylamide (49:1 )/Tris-Borate EDTA (0.5x) gel with and 
without 10% (v/v) glycerol. Subsequently, electrophoresis was performed at room 
temperature for 16 hours at 6 or 3W respectively. 
Sequence Analysis 
Direct sequencing of the double stranded PCR products that showed a shift on the SSCP 
gels was performed as described previously (109). Amplified PCR products were 
purified using the magic PCR preps1"1 DNA purification system (Promega, Madison, WI, 
USA). The PCR primers were used for sequencing in the dsDNA cycle sequencing 
system (Life Technologies, Ine, Gaithersburg, MD, USA). Electrophoresis was 
performed on 6% Polyacrylamide (19:1) gels containing 7 M ureum. 
Statistical Analysis 
The Kaplan-Meier method was used to estimate survival probability as a function of 
time. Differences in survival were analyzed by a log-rank test. The Chi-square test (with 
Yates correction if relevant) was used for the other correlations. 
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Table 1. p53 Overexpression, clinical and pathological data for each patient. 
Case 
no. 
1 
2 
3 
4 
5 
6 
6 ree. 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
17 ree. 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
Age 
(yr) 
77 
81 
77 
73 
66 
55 
54 
50 
88 
50 
68 
75 
92 
62 
58 
71 
79 
77 
72 
81 
73 
53 
79 
81 
53 
70 
47 
67 
72 
79 
59 
73 
68 
63 
74 
74 
80 
44 
82 
Stage/Grade 
a/1-2 
a/1 
a/1 
a/1 
a/3 
a/1-2 
a/2 
a/1 
a/1 
a/2 
a-1/2 
a-1/1 
1/3 
1/2 
1/2 
1/2 
1/1 
1/2 
a/3 
1/2 
1/2 
2/2 
2/2 
2/3 
2/3 
2/2 
2/3 
2/3 
2/3 
>2/3 
>2/3 
>2/3 
>2/3 
2-3/3 
2-3/3 
3/3 
3/3 
3b/2 
3b/3 
4/3 
4/2 
p53 Immuno-
positivity* 
+ + 
-
-
-
+ + 
-
+ 
-
-
-
+ + 
-
-
+ 
-
+ 
-
+ 
-
+ 
+ 
-
+ 
+ 
+ + 
-
+ + 
+ + 
-
-
+ + + 
+ 
+ + 
+ + 
+ + + 
+ + 
+ + + 
+ + 
-
-
-
Recurrences 
no 
a/2, 
no 
no 
a/2, 
a/2, 
no 
a / 1 , 
no 
no 
1/2, 
a/2. 
a/2, 
no 
a /1 , 
a/2, 
a/3, 
no 
a/2. 
8 months 
8 months 
4 months 
8 months 
4 months 
6 months 
11 months 
9 months 
4 months 
3 months 
6 months 
Survival 
(months) 
31 
> 6 5 
> 5 8 
> 5 5 
23 
> 6 8 
> 4 6 
> 8 4 
52 
> 6 9 
> 3 7 
> 7 2 
73 
> 4 0 
> 5 0 
> 7 5 
49 
> 5 8 
> 4 4 
9 
8 
> 5 0 
4 
6 
7 
3 
8 
> 2 0 
> 8 5 
10 
3 
2 
2 
5 
10 
> 3 9 
> 5 3 
29 
5 
Treatment' 
TURT 
TURT 
TURT 
TURT,Ch 
TURT,Ct,R,Ch 
TURT,BCG,Ct 
TURT 
TURT,BCG,Ch 
TURT.Ch 
TURT 
TURT 
TURT.BCG 
TURT,Ch 
TURT,Ch 
TURT,BCG 
TURT 
TURT,Ch 
TURT.Ch 
TURT,Ch,BCG 
TURT 
TURT,Ch,Ct 
TURT,R,lndium 
Ct 
TURT 
TURT.Ch 
TURT,Ch 
TURT,Ch 
TURT.Ch,R 
TURT.Ch 
TURT.Ct 
TURT.R 
TURT,R 
TURT 
TURT,R 
Ct,Ch 
Ct 
TURT,R,Ct 
TURT.Ct 
TURT 
A
 Number of positive cells: -, 0%; + , 1-10%, + +, 10-50%; + + +, >50%. ree, recurrence; 
" Ch, chemotherapy; Ct, cystectomy; R, radiotherapy; TURT, transurethral resection of the tumor, 
BCG, bacillus calmette-guenn instillations. 
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Results 
Iininuiiostaining patterns 
The DO-7 staining patterns of the four groups are shown in Figure 1. We defined a 
tumor as p53 positive if more than 10% of the tumor cells showed nuclear p53 
expression. Of the 41 tumors studied, 13 showed p53 overexpression (Table 1). 
ι 
• I. · 
Figure 1. Immunohistochemical staining of p53 expression in transitional cell carcinomas 
using p53 antibody DO-7 A. Stage Та grade 2 tumor, no tumor cells stained (0% = -) B. 
Stage T2 grade 2 tumor, a few tumor cells are stained (1-10% = +) C. Stage T2 grade 3 
tumor, heterogeneous staining (10-50% = + +) D. Stage T3 grade 3 tumor, clearly more 
than 5 0 % of tumor cells show nuclear p53 overexpression ( > 5 0 % = + + +) Original 
magnification, times 400. 
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Correlation between tumor grade/stage and p53 overexpression 
p53 overexpression was found in 9% of the grade 1, 23% of the grade 2 and 60% of the 
grade 3 tumors. Overexpression of p53 was found in 16% of the superficial tumors and 
in 50% of the invasive tumors (p<0.05) (Table 2,3). p53 Mutations found by SSCP 
analysis showed a high correlation with both increasing grade (p<0.001) and stage 
(jK0.001)(233). 
Table 2. Correlation between p53 overexpression and grade. 
Grade 
1 
2 
3 
A
 Number of positive 
-
9 
6 
4 
cells: -
p53 immuno-positivity* 
+ 
1 
4 
2 
, 0%; +, 1-
Table 3. Correlation between p53 
Stage 
superficial 
invasive 
-
10 
7 
+ + 
1 
3 
6 
in) 
+ + + 
0 
0 
3 
10%; + +, 10-50%; + + +, 
overexpression 
p53 immuno-positivity* 
+ 
6 
3 
+ + 
3 
7 
in) 
and stage 
+ + -ι-
Ο 
3 
% immL 
, > 5 0 % 
% immi 
ino-positivrty 
% 
9% 
23% 
60% 
ino-positivity 
% 
16% 
50% 
A
 Number of positive cells: -, 0%; +, 1-10%; + + , 10-50%; + + +, > 5 0 % . 
Correlation between p53 overexpression and survival 
The survival according to p53 overexpression is shown in Figure 2. For the whole group, 
a shorter survival time of patients with p53 overexpression was observed (Chi-square: 
8.00, p<0.01, Figure 2a). Although statistical analysis was not possible, because of the 
small number studied, we observed a shorter survival time for patients with superficial 
bladder cancer that showed p53 overexpression (Figure 2b). Within the group with 
invasive disease, no significant difference in survival time between the patients with and 
without p53 overexpression was seen (Figure 2c). 
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^ 4 0 _ 
time in months 
hi h 
negative (n = 16) 
- H -
positive (п Э) 
и — ι ι ι — ι — ι — ι — ι — I I 
0 β 12 18 24 30 36 42 4B 64 60 
time in months 
time in months 
Figure 2. Kaplan Meier survival curves of bladder cancer patients according to the 
presence or absence of overexpression of the p53 protein. 
A. All patients ( P < 0 . 0 1 , log rank test). B. Patients with superficial (pTa, pT1) tumors (not 
significant). С Patients with muscle invasive disease (not significant). 
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Table 4. Relationship between p53 mutations analyzed by PCR-SSCP and p53 
overexpression by immunostaining. 
P53 mutatior 
No mutation 
Mutation 
Exon 5 
Exon 6 
Exon 7 
Exon 8 
i/SSCP 
-
18 
2 
1 
0 
0 
1 
Immunostaining* (n) 
+ 
8 
0 
0 
0 
0 
0 
+ + 
7 
3 
1 
0 
1 
1 
+ + + 
0 
3 
1 
1 
0 
1 
< 1 0 % > 1 0 % 
(%) 
77 23 
25 75 
'Number of positive cells: - , 0 % ; +, 1-10%; + + , 10-50%; + + +, > 5 0 % . 
Comparison between p53 overexpression with p53 mutations found by PCR-SSCP 
The overall comparison of p53 mutations analyzed by PCR-SSCP and p53 
overexpression assessed by immunohistochemistry (IHC) is shown in Table 4. The 
sensitivity of IHC, defined as percentage of IHC-positive tumors among tumors with 
identified mutation, was 75%. The specificity of IHC, defined as percentage of IHC-
negative tumors among neoplasms without a p53 mutation, was 77%. Despite the good 
concordance between p53 mutation and p53 protein overexpression (p<0.02) , 23% 
(7/31) of the tumors without a p53 mutation as assessed by SSCP analysis showed p53 
overexpression. 
Table 5. Comparison immunostaining and PCR-SSCP analysis for mutants. 
His· 
Case 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
topathology 
Stage/Grade 
> 2 / 3 
3/3 
4/3 
2/3 
2/3 
2-3/3 
2-3/3 
> 2 / 3 
Exon 
5 
8 
5 
8 
5 
8 
6 
7 
p53 Mutation/SSCP 
Codon 
179 
285 
166 
282 
158 
285 
215 
259 
Amino acid change 
CAT -> TAT (His -> Tyr) 
GAG -> AAG (Glu -> Lys) 
TCA -> TGA (Ser -> umber) 
del. G -> frameshift 
CGC -> CTC (Arg -> Leu) 
GAG -> AAG (Glu - • Lys) 
AGT -> GGT (Ser -У Gly) 
GAC -> GTC (Asp -y Val) 
p53 Overexpression* 
+ + + 
+ + + 
-
-
+ + 
+ + 
+ + + 
+ + 
Number of positive cells:-, 0%; +, 1-10%; + + , 10-50%; + + +, > 5 0 % . 
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Table 5 shows the eight p53 mutants found by PCR-SSCP analysis. They all showed 
p53 overexpression except for cases 3 and 4, which showed no p53 immunoreactivity at 
all. These two cases contained а С to G transversion at codon 166 leading to a stopcodon 
and a deletion of a guanine nucleotide in codon 282, resulting in a frameshift. 
Discussion 
This study compares the overexpression of the p53 protein assessed by IHC with p53 
mutation determined by means of SSCP analysis in bladder cancer. We looked at both 
clinical and biologic aspects of p53 alterations. We chose a cut off of 10% p53 positive 
tumor cells for p53 overexpression. The appearance of occasionally stained cells in 
tumors, which we scored as negative, can be explained by the existence of clones of 
cells with a p53 mutation or by the occurrence of a genotoxic event that raises levels of 
wild type p53 protein in normal cells, resulting in cell cycle arrest (80,111). More 
detailed examination of microdissected focally stained areas by means of mutation 
analysis (SSCP) has to be performed to address this problem and to check the biologic 
importance of this phenomenon. 
The overexpression of p53 as assessed by IHC correlates with grade and stage (p<0.05). 
However, correlation between mutations in the p53 gene as determined by SSCP 
analysis and grade and stage was higher (pO.001) (233). In concordance with other IHC 
studies (47,126) we demonstrated that p53 overexpression is an unfavorable prognostic 
factor for bladder cancer patients (pO.01). No association between p53 overexpression 
and decreased survival was found for invasive tumors, in contrast with other studies. 
Differences in the treatment of the patients and the different Ab and scoring systems 
used might explain these differences. Esrig and coworkers (47) showed that p53 
overexpession is a significant predictor of tumor progression if the disease was confined 
to the bladder. However, no association between p53 overexpression and tumor 
progression was found if the disease is not confined to the bladder (pT3b, pT4). Because 
of the relatively small number in our study, we can not compare these two groups. The 
results of our study show that p53 overexpression has no additional prognostic value 
over stage, whereas for this same group of patients we found that E-cadherin may have 
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additional prognostic value over stage ( 18). Apparently, other mechanisms can lead to 
tumor progression and they may override or bypass the function of p53. 
The Kaplan Meier curves show the same result for p53 overexpression and p53 mutation 
(233) when the whole group and the invasive tumors are studied. For superficial tumors, 
however, three patients showed p53 overexpression without a mutation confirmed by 
SSCP analysis. Although this was not statistically significant, a trend was observed 
toward worse survival for the patients showing p53 overexpression. This was not 
observed when p53 mutations were analyzed, because we found no mutations at all in 
the group of superficial tumors. In high grade pTl tumors, p53 overexpression had 
predictive value for progression of disease (181). These results, combined with the 
correlation of p53 overexpression with increasing grade and stage as shown here, imply 
that p53 overexpression plays a role in the progression of bladder cancer. 
Analysis of p53 mutations at the molecular genetic level is rather difficult and time 
consuming and therefore is not suitable for routine use. IHC, however, is a standard 
technique in pathology laboratories. There is a good concordance between p53 mutation 
and p53 overexpression in relation to grade, stage and survival, so IHC detection of p53 
alterations is preferable as a predictor of prognosis. Furthermore, immunohistochemistry 
might reveal anomalies in the p53 pathway other than p53 mutations (see below). 
A good concordance between p53 mutation by SSCP and p53 overexpression by IHC 
(p<0.02) was observed. This strong correlation between high levels of p53 protein and 
mutation in the p53 gene has previously been described for a number of tumor types, 
and this led to the hypothesis that mutant p53 gene products are characterized by 
conformational changes of the protein, resulting in a higher stability and consequently in 
accumulation of the protein. However, we have observed discrepancies between p53 
mutation and p53 overexpression. 
Of the eight tumors with a p53 mutation as assessed by SSCP, two tumors showed no 
p53 immunoreactivity at all. In one tumor sequence analysis showed a transversion in 
codon 166 of exon 5 generating a stop codon and thereby a truncated protein, which 
does not contain the nuclear localization domain at amino acids 316 to 325 (238). In the 
other tumor a deletion of a guanine nucleotide found in codon 282 of exon 8 gave rise to 
a frameshift, which also affected the downstream nuclear localization sequence. In both 
cases, the loss of the nuclear localization signal most likely prevented nuclear 
accumulation, and therefore IHC detection was impossible. 
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In addition to these "false negatives", which can still be explained by the proposed 
theory of extended stabilization, we observed p53 overexpression in 23% of the tumors 
without any sign of p53 mutation as assessed by SSCP. This p53 overexpression without 
a concomitant mutation was also found in a considerable number of bladder tumors in 
two other studies (34,46). Although we studied exons 5 to 8, which are known to contain 
the majority of the p53 mutations (169) mutations outside this region and intron 
mutations might explain this result. Moreover, although SSCP is a sensitive method for 
detecting mutations (31 ), not all mutations are detected by this technique. The presence 
of nonneoplastic tissue, although reduced to <30%, can lead to a negative SSCP result if 
the percentage of tumor cells overexpressing p53 is approximately 10%. This cannot be 
the explanation for p53 overexpression in the 23% of the tumors without a SSCP proven 
p53 mutation, because most of these tumors contained at least 20% of p53 
overexpressing tumor cells. 
All off the mechanisms leading to p53 overexpression are not yet fully understood. 
According to the already mentioned hypothesis, mutant p53 would always be stable and 
wild type p53 would be unstable. Thus the tight correlation between mutation and 
overexpression could indicate a causal relationship. However, this is not always true. In 
fibroblasts obtained from Li-Fraumeni patients who carried heterozygote germ-line p53 
mutations, the mutant p53 protein did not accumulate to a high level and was unstable 
like the wild type p53 (112). By contrast, in the tumors of these patients, when the wild 
type allele was lost, the mutant p53 protein did accumulate. Clearly, p53 mutation per 
se does not cause p53 protein accumulation. 
Alternatively, wild type p53 can accumulate in some circumstances, e.g., as a result of 
complexing with viral oncoproteins (110,124,184) and also with the cellular oncoprotein 
mdm2 (148). Accumulation of wild type p53 in normal tissue was shown to occur in a 
novel cancer family syndrome (7). One can hypothesize that anomalies elsewhere in the 
p53 pathway can result in stabilization of p53 proteins as well as in the ability to ignore 
its growth-suppressive commands. 
We found p53 overexpression in 23 % of the cases without any sign of a mutation, 
which is in concordance with two other studies (34,46), so we suspect that some other 
event(s) in addition to mutation plays a role in stabilization. The viral oncoproteins are 
not relevant for the human system. The mdm2 oncoprotein has been implicated in the 
progression of bladder cancer (119). Whether mdm2 overexpression represents an 
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alternative to p53 mutation in inactivating the p53 regulatory pathway is still unclear. 
Events other than mutation that lead to stability remain to be elucidated. It is noteworthy 
that p53 can accumulate in normal cells upon DNA damage. Thus some tumor cells 
behave as if they were in a permanent state of DNA damage (112). Additional research 
is necessary to characterize the signals that trigger this state and to understand the 
mechanisms through which this overexpression reflects alteration of p53 function and 
consequently gives rise to an altered phenotype in cancer cells. 
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P53 mutations have no additional prognostic value 
over stage in bladder cancer. 
Jacqueline AM Vet1, Pierre Paul Bnnguier1, Pino J Poddighe2, Herbert FM Karthaus3, Frans 
MJ Debruyne , Jack A Schalken 
Abstract 
Evidence is accumulating that the tumor suppressor gene p53 is involved in the development of 
bladder cancer Therefore we studied p53 mutations in 47 bladder cancers obtained from 45 
patients using polymerase chain reaction/ single-strand conformation polymorphism (PCR-
SSCP) analysis Eight out of 24 invasive tumors appeared to have a p53 mutation while no p53 
mutations were found in the superficial tumors All the p53 mutations were found in grade 3 
tumors 
The tumors with altered p53 showed a higher frequency of allelic loss (FAL) compared to the 
tumors without a mutation (55 8% versus 21 1%, p<0 05, by Chi-square test) This increase in 
FAL suggests a correlation between p53 mutations and genetic instability 
A significant correlation between mutated p53 and poor survival in the whole group studied 
was found (p<0 001, by log rank test) However, within the group of muscle-invasive tumors 
the occurrence of p53 mutations had no additional prognostic value Therefore, even though p53 
mutations were found in aggressive tumors, the clinical usefulness of its detection seems 
limited 
Nevertheless, these results implicate that p53 is involved in the clinical behavior of bladder 
cancer, and especially its role in the progression of superficial cancer to invasive disease needs 
further attention 
Departments of Urology' and Pathology2, University Hospital, Nijmegen, The Netherlands and 
the department of Urology3, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands This 
study was supported by the Dutch cancer foundation, NUKC 9102 (J A M V ) and IKL 8807 
(P J P) and the foundation for urological scientific exchange (FUSEX) (Ρ Ρ В ) Published in 
Br J Cancer 70 496-500, 1994 
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Introduction 
Bladder cancer is the fifth most common cancer in the western male population, with an 
annual incidence of 20 cases per 100,000. The incidence in women is lower, about 5 
cases per 100,000 are diagnosed annually (173). Transitional cell carcinoma of the 
bladder is divided in two groups: A) superficial (pTis, pTa, pTl) and B) muscle invasive 
(pT2, pT3, pT4) disease. Most superficial bladder cancers have a good prognosis, 
however 10-25% clinically progress to a more aggressive state, showing an increase in 
grade and/or infiltration into the muscle layer. pTl tumors invade the lamina propria and 
have a higher incidence of progression than the pTa tumors, which are confined to the 
urothelium. Patients with invasive tumors usually present de novo and have a worse 
prognosis. Non random chromosomal changes were observed in bladder cancer, for 
example, in cytogenetic studies monosomy of chromosome 9 has been reported 
(70,88,202,231). Using restriction fragment length polymorphism analysis (RFLP), 
allelic loss of chromosomes 9, 11 and 17 in bladder cancer has been demonstrated (221). 
Abnormalities of chromosome 11 ρ appeared to be more frequent in invasive- than in 
superficial tumors and monosomy of chromosome 9 was not correlated with grade or 
stage. Loss of heterozygosity (LOH) of chromosome 17p occurred only in high-grade 
(G3) tumors (159). The p53 gene is considered the candidate tumor suppressor gene on 
chromosome 17p, since in cancer development, frequently one of the two alleles is lost 
and the remaining is mutated (6,87). Recently, it has been suggested that p53 acts as a 
cell cycle control protein at the level of Gl to S phase transition (99,129,253). The loss 
of this function may result in an increased genetic instability (253). In bladder cancer it 
has been shown by means of subcloning and sequencing of exon 5 through 9 that 17p 
allelic loss is strongly associated with p53 mutation (9 out of 10 cases) and that out of 18 
invasive tumors 6 1 % have a p53 mutation (199). This association of p53 mutations and 
invasive tumors was confirmed in another study by using the technique of PCR-SSCP 
(64). 
We studied p53 mutations in a group of 45 patients with bladder cancer, using PCR-
SSCP analysis. Besides a correlation with grade and stage we investigated the prognostic 
significance of p53 mutations. Since p53 mutations are thought to be associated with 
genetic instability (99,129,253) we also studied the correlation of p53 mutations and 
genetic instability evaluated by the frequency of allelic loss. 
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Materials and methods 
Tumor specimens 
Twenty-three snap frozen superficial carcinomas (pTa-pTl) and 24 muscle invasive 
carcinomas (pT>2) obtained from 45 patients have been analyzed. Superficial tumors 
comprised 2 recurrences of previously analyzed tumors. Among the invasive tumors 2 
were squamous cell carcinomas. All the other tumors were transitional cell carcinomas. 
Pathological and clinical data for the patients are summarized in Table I. Genomic DNA 
was extracted from step-sectioned tumors (>70% tumor cells) (144). 
PCR-SSCP and sequence analysis 
PCR-SSCP and sequence analysis were performed as described in chapter 2. 
Restriction fragment length polymorphism 
DNA probes used : chromosome 9q: EFD 126 (152), chromosome lip: H-ras (172), 
chromosome 16q: pV962 (135) and 79.2.23 (19), chromosome 17p: 144D6 (192), 
chromosome 18q: 15.65 (50). RFLP analysis was performed on the 24 patients from 
whom normal DNA was available (168). The RFLP results were used to determine the 
frequency of allelic loss (FAL), also called fractional allelic loss (236). 
Statistical analysis 
The Kaplan-Meier method was used to estimate survival probability as a function of 
time. Differences in survival were analyzed by a Log-rank test. Chi-square test was used 
for the other correlations. 
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Table 1 . p53 Mutations, clinical and pathological data for each patient. 
p53 Mutations 
Case no 
1 
2 
3 
4 
5 
6 
7 
7 ree. 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
19 ree 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
Age 
(vr) 
77 
75 
72 
68 
66 
66 
49 
62 
53 
42 
88 
44 
65 
68 
86 
76 
53 
64 
85 
71 
68 
81 
73 
49 
79 
81 
53 
70 
47 
62 
65 
83 
79 
59 
73 
73 
76 
68 
63 
74 
50 
70 
75 
44 
82 
Stage/Grade 
a/1-2 
a/1 
a/1 
a/1 
a/3 
a/2 
a/2 
a/2 
a/1 
a/1 
a/1 
a/2 
a-1/2 
a-1/1 
1/3 
1/2 
1/2 
1/2 
1/1 
1/2 
a/3 
1/2 
1/2 
2/2 
2/2 
2/3 
2/3 
2/2 
2/3 
2/3 
2/3 
>2/3 
>2/3 
>2/3 
>2/3 
>2/3 
2-3/3 
2-3/3 
2-3/2,SCC 
2-3/3 
3/3 
3/3 
3/2.SCC 
3b/2 
3b/3 
4/3 
4/2 
Exon/Codon 
(P) 
(P) 
(P) 
(P) 
5/158 
8/282 
5/179 
7/259 
8/285 
6/215 
8/285 
5/166 
CGC 
Amino acid change 
-> CTC (Arg -, 
del. G -> frameshift 
CAT 
GAC 
GAG 
AGT 
-> TAT {His -> 
Leu) 
Tyr) 
-> GTC (Asp -> Val) 
-> AAG {Glu -> 
-> GGT (Ser -> 
GAG / AAG (Glu -> , 
TCA - • TGA (Ser -> 
'Lys) 
Gly) 
Lys) 
umber) 
Survival 
(months) 
31 
>41 
>38 
>41 
23 
>57 
>45 
> 6 4 
>61 
>65 
52 
>39 
>22 
>55 
>58 
9 
>37 
>55 
>45 
> 3 6 
> 3 6 
9 
8 
>36 
4 
6 
7 
3 
8 
>27 
>66 
21 
10 
3 
2 
9 
32 
2 
5 
10 
5 
> 2 8 
> 4 0 
29 
5 
Treatmei 
TURT 
TURT 
TURT 
TURT.C 
TURT,Ct,R,CH 
TURT.Ct 
TURT,BCG,Ct 
TURT 
TURT.BCG 
TURT.BCG.Ch 
TURT.Ch 
TURT 
TURT 
TURT.BCG 
TURT.Ch 
TURT.Ch 
TURT.BCG 
TURT 
TURT.Ch 
TURT.Ch 
TURT.Ch.BCG 
TURT 
TURT.Ch.Ct 
TURT,R,Indium 
Ct 
TURT 
TURT.Ch 
TURT.Ch 
TURT.Ch 
TURT.Ch,R 
TURT.Ct 
TURT.R 
TURT.Ct 
TURT.R 
TURT.R 
TURT 
TURT.Ct.R 
TURT 
TURT.R 
Ct.Ch 
TURT 
Ct 
TURT.R.Ct 
TURT.Ct 
TURT 
SCC, squamous cell carcinoma; (p), polymorphism codon 213; ree, recurrence, 
A
 Ch, chemotherapy; Ct, cystectomy, R, radiotherapy; TURT, transurethral resection of the tumor, 
BCG, bacillus calmette-guerin instillations. 
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Results 
p53 mutations in bladder cancer 
Table 1 summarizes the results of the PCR-SSCP and sequence analysis of the p53 gene 
in bladder tumors of 45 patients. Eight mutations were found in invasive tumors: three in 
exon 5, one in exon 6, one in exon 7 and three in exon 8. Seven out of the eight 
mutations found were point mutations, while one appeared to be a deletion of a G, 
leading to a frameshift. We found four transitions: two G to A, one A to G, one С to Τ 
and three transversion: one С to G, one G to Τ and one A to T. In three patients with a 
superficial tumor a similar shift in the SSCP pattern of exon 6 was observed. One of 
these also showed loss of heterozygosity of chromosome 17p. After sequencing it 
appeared that the shift in the SSCP pattern was due to a silent alteration of CGA to CGG 
at codon 213. This polymorphism was already described before (139). No mutations 
were found in the squamous cell carcinomas. 
Correlation between tumor stage/grade and p53 mutations 
All the p53 mutations are found in grade 3 tumors, as is shown in Table 2a (pO.001). In 
the group of superficial tumors no mutations have been found, while the invasive tumors 
have in 8 out of 24 (33%) cases a p53 mutation (pO.001) (Table 2b). This is in good 
agreement with previous observations (64,199). 
Table 2a. Relationship between p53 mutation and grade. 
Grade 
1 
2 
3 
Table 2b. 
Stage 
Superficial 
Invasive 
Relati 
p53 mutation 
negative positive 
11 0 
15 0 
11 8 
lonship between p53 mutation 
p53 mutation 
negative positive 
21 0 
16 8 
and stage. 
% mutations 
0 
0 
42 
% mutations 
0 
33 
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Table 3a. Allelic loss of chromosomes 9q, 11 p, 16q, 17p, 1 8q and p53 mutations in 
bladder tumors. 
Case RFLP analysis 
no. Stage/Grade p53 Mutation Chromosomal region 
1 
2 
3 
4 
5 
6 
7 
7 ree. 
8 
8 ree. 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
a/1 
a/1 
a/1 
a/1 
a/1 
a/1-2 
a/1-2 
a/1-2 
1/2 
a/3 
a/2 
a/2-3 
1/2 
1/2 
1/2 
1/2 
1/2 
1-2/1-2 
2/3 
2/3 
> 2 / 3 
> 2 / 3 
3/3 
3/3 
3/3 
4/3 
. 
-
-<P) 
-
-
-
-
-(p) 
-(P) 
-
-
-(P) 
-
-
-
-
-
-
+ 
-
+ 
-
+ 
+ 
9q 
• 
О 
О 
о 
о 
о 
• 
• 
• 
• 
о 
NI 
• 
• 
О 
о 
NI 
О 
О 
NI 
NI 
• 
• 
NI 
NI 
• 
11p 
о 
о 
о 
о 
NI 
О 
• 
• 
О 
о 
NI 
О 
О 
• 
О 
о 
• 
NI 
О 
NI 
NI 
О 
О 
О 
NI 
NI 
16q 
• 
О 
О 
о 
о 
о 
о 
о 
о 
о 
о 
о 
о 
о 
о 
о 
о 
о 
• 
о 
о 
о 
о 
о 
• 
о 
17р 
о 
о 
о 
о 
NI 
о 
о 
о 
• 
• 
• 
о 
о 
о 
о 
о 
о 
о 
о 
• 
о 
• 
NI 
о 
• 
• 
18q 
О 
NI 
О 
NI 
О 
О 
О 
О 
ND 
• 
• 
NI 
NI 
NI 
NI 
О 
• 
О 
NI 
О 
NI 
О 
ND 
ND 
ND 
O 
-, no p53 mutation; + , p53 mutation; O, no LOH; · , LOH; NI, not informative; 
ND, not determined; r e e , recurrent tumor; (p), polymorphism at codon 213. 
Table 3b. Frequency of allelic loss according to p53 mutation. 
p53 Mutation Number of tumors FAL% 
negative 22 21.1 
positive 4 55.8 
Relation between p53 mutations and frequency of allelic loss 
As a measure for genetic instability we used frequency of allelic loss (FAL). FAL was 
based on RFLP analysis using probes for chromosomes 9q, l ip, 16q, 17p and 18q 
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(Table За). LOH of 17p was found in 7 tumors. Four tumors showed a p53 mutation, 
while in two a polymorphism at codon 213 was found. No mutations were found in the 
tumors without 17p LOH. The tumors with a p53 mutation show a FAL of 55.8%, those 
without a mutation have a FAL of 21.1% ( p<0.05) (Table 3b). 
Correlation of p53 mutation and survival 
The survival according to p53 mutation for the whole group of 45 patients is shown in 
the Kaplan-Meier curve (Figure la). The patients with a p53 mutation survived for a 
shorter period of time (χ2 = 11.25, pO.001). There was no significant association 
between the presence of a p53 mutation and decreased survival among patients with 
invasive disease (χ = 1.46, n.s.) (Figure lb). 
time in months 
Figure 1. Three year survival (%) of bladder cancer patients according to the presence or 
absence of p53 mutations. A. All patients (p < 0.001 by log rank test) B. Patients with 
muscle invasive tumors (p = not significant) 
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Discussion 
In this study, we examined mutations in the p53 gene by PCR-SSCP analysis. We show 
that the occurrence of p53 mutations correlates with grade and stage, which is in 
concordance with previous studies (64.199). A p53 mutation was found in 8/24 (33%) of 
the invasive tumors, which were all grade 3. 
The p53 tumor suppressor gene is known to be mutated in many types of cancer (87) and 
during tumor progression one of the two alleles is often lost resulting in a reduction of 
growth control (6). However, some p53 mutations are known to be dominant negative: 
the protein produced by the mutated allele has the ability to bind and inactivate the 
remaining wild-type product (237). In our study we did not find any mutation without 
LOH of 17p. On the contrary one patient with 17p LOH has no p53 mutation. It could be 
that the mutation is outside the region of the p53 gene studied or that a second locus 
distinct from p53 is involved (188). 
Wild-type p53 has been suggested to be a cell cycle control protein since progression 
from Gl to S phase is often blocked in cells expressing high levels of this protein 
(99,129,253). It has been shown that cells without wild-type p53 protein failed to show 
growth arrest (when placed in a condition unfavorable for the S-phase completion) and 
gene amplification occurs (253), which can be considered as a form of genetic 
instability. As p53 mutations are known to occur in bladder cancer (64,199), we used 
frequency of allelic loss as an indicator for genetic instability (236). The high frequency 
of allelic loss found in tumors with a p53 mutation (55.8%, p<0.05) suggests a 
correlation with genetic instability. This increase in allelic loss in tumors with a p53 
mutation could be explained by an altered Gl-S cell cycle checkpoint which can be the 
result of the loss of the wild-type p53 function. The loss of certain alleles, e.g. those 
harboring tumor suppressor genes, could provide selective advantages during tumor 
progression by generating variants with a more aggressive phenotype (52). FAL showed 
no significant correlation with grade or stage. 
In breast cancer p53 mutations are inversely correlated with survival (2). This study is 
the first report investigating the prognostic significance of p53 mutations in bladder 
cancer. The results demonstrate that p53 mutations are an unfavorable prognostic factor 
(pO.001) for the whole group studied. However, among patients with invasive tumors 
there was no significant association between the presence of a p53 mutation and a 
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decreased survival. Therefore patients without a p53 mutation are not ensured to have a 
good prognosis. There are other features that can lead to an inactive p53 protein: such as 
complexing with other proteins (148), or other genetic events can occur that result in a 
poor prognosis. EGFR positivity is shown to be associated with tumor progression and 
decreased survival (154). Also no significant difference between EGFR positivity and 
survival among patients with invasive tumors was found. Furthermore, recently it has 
been shown that decreased E-cadherin expression correlates with the clinical 
aggressiveness of bladder cancer (18). 
The variable order of appearance of genetic alterations in oncogenesis suggests that 
rather accumulation, than the order of occurrence, is important for tumor progression 
(52). The increased frequency of allelic loss we find in the tumors with a p53 mutation 
can lead to tumor progression and poorer prognosis. But as mentioned above there are 
other mechanisms which can lead to tumor progression and these may overrule or 
bypass the function of p53. 
Recently immunohistochemical studies have shown p53 overexpression to be correlated 
with poor survival (126,181). In pTl bladder tumors Sarkis et al. found a clear 
correlation between nuclear overexpression of p53 protein and disease progression. The 
study of Lipponen showed a significant correlation between p53 overexpression and 
decreased survival for the entire cohort and for the muscle-invasive tumors. However for 
the pTa and pTl tumors only a trend was found. In muscle-invasive tumors, we found 
no association between p53 mutations and decreased survival. This difference stresses 
again the discordance of p53 immunohistochemistry and p53 mutation analysis (214). 
The discrepancy in prognostic value for p53 mutations in superficial disease found in the 
two immunohistochemical studies, can be the result of the use of different antibodies 
and the scoring system used. We found no p53 mutations in superficial tumors, which 
can be explained by the lack of grade 3 tumors in this group. 
The results of our study indicate that the presence of a p53 mutation is an unfavorable 
prognostic factor for the whole group studied, but it has no additional prognostic value 
for the group of muscle invasive tumors. The step at which p53 mutations occur in the 
tumor progression cascade of bladder cancer is still unclear. In this respect grade 3 
superficial tumors deserve more attention. In general superficial bladder cancer has a 
good prognosis, however, 10-25% of these tumors progress to an invasive stage. 
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Therefore the correlation between prognosis and p53 mutation in this subgroup is of 
particular interest. 
Furthermore the discordance of immunohistochemical and p53 mutation analysis 
indicate that comparative analysis of p53 mutations and overexpression of the p53 
oncoprotein in progression of the pTa and pTl tumors are necessary. 
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Predictive value of p53 mutations analyzed in bladder washings 
for progression of high risk superficial bladder cancer. 
Jacqueline AM. Vet, J. Alfred Witjes, Salvatore AE. Marras, Daphne Hesseis, Henk G. van der 
Poel, Frans MJ Debruyne, Jack A. Schalken. 
Abstract 
To assess the value of p53 mutations in predicting the progression of superficial bladder cancer 
(TCC) and to define exactly when p53 mutations occur in the process of tumor progression, 80 
consecutive bladder washings from 26 high risk (indicated by quantitative karyometric analysis) 
superficial TCC patients were examined by Single Strand Conformation Polymorphism 
(SSCP). Six out of 13 patients who experienced clinical progression (to pT>2) were found to 
have a p53 mutation in one or more of their bladder washings. In the control group (no 
progression to invasive disease) only 1 out of 13 patients had a p53 mutation. For these high 
risk superficial TCC patients the occurrence of a p53 mutation has a positive predictive value of 
86% for the progression of disease. A negative predictive value of 63% was observed. 
Moreover, since p53 mutations were found in samples prior to progression (with a mean of 8 
months) it could identify patients who need a change in the treatment strategy in order to 
prevent progression to invasive disease. In spite of these promising results, it is obvious that to 
increase not only the positive predictive value but especially the negative predictive value of 
this procedure to predict progression, additional prognostic markers are still needed. 
Department of Urology, University hospital Nijmegen, Nijmegen, The Netherlands. This work 
was supported by a grant from the Dutch Cancer Society (NUKC9102) Clinical Cancer 
Research in press. 
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Introduction 
Transitional cell carcinoma (TCC) is the most common histologic type of bladder 
cancer, presenting with a wide spectrum of clinical and pathological appearances. 
Superficial TCC accounts for approximately 80% of all newly diagnosed tumors in the 
bladder (204). Thirty to 90% of these tumors will recur depending on stage, grade, 
multifocality and treatment modality, however, only 10-25% become invasive or 
metastasize during the course of the disease (74,102). Early identification of patients 
whose superficial bladder tumors will progress is very important, since a change in their 
treatment strategy can have a major impact on the outcome of disease. The morbidity of 
cystectomy, which at the moment is the only treatment to prevent progression to 
invasive disease, emphasizes the urgent need for markers that identify patients at risk for 
tumor progression. 
The p53 tumor suppressor gene, located on chromosome 17p 13.1, is known to be 
involved in the development of bladder cancer. Allelic deletions of 17p were 
predominantly observed in invasive tumors and to a lesser extent in high grade 
superficial TCC, but were absent in low grade Ta tumors (36,77,159). Mutations in the 
p53 tumor suppressor gene frequently occur in bladder cancer and appear to correlate 
with grade and stage (64,199,233). The relatively high frequency of p53 mutations in 
T2-T4 tumors compared to Tl tumors suggests their involvement in the progression of 
Tl tumors to invasive disease (207). However, the exact point at which p53 mutations 
occur during tumor progression from superficial (Ta) tumors to lamina propria invasive 
(Tl) and muscle invasive (T2-T4) tumors is still unclear. 
The tumor suppressor protein p53 appears to play a role as transcriptional regulator 
(54,134) and acts as a cell cycle control protein at the level of Gl to S phase transition 
(99,129). In case of DNA damage, p53 can delay the progression through the cell cycle, 
to permit DNA repair (134) or can initiate programmed cell death (apoptosis) (132). The 
upregulation by p53 of p21, an inhibitor of Gl cyclin-dependent kinases, appears to be 
responsible for p53 mediated growth arrest (94). Recently, Smith and coworkers showed 
that Gadd45 which is also upregulated by p53, probably serves as a link between the 
p53-dependent cell cycle checkpoint and DNA repair (203). The loss of these p53 
regulatory functions can result in replication of incorrect DNA, leading to increased 
genetic instability (253). 
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From a large prospective study in which approximately 3000 bladder washings were 
investigated by quantitative karyometric analysis (228) we selected 26 patients who 
were indicated to be high risk (i.e. suspected for recurrences) on basis of this analysis. 
We studied the value of p53 mutations as a additional prognostic marker in this group of 
high risk superficial TCC patients, using PCR-SSCP analysis. In order to define when 
p53 mutations occur during natural history of these tumors we analyzed consecutive 
bladder washings from the same patients. 
Materials and methods 
Specimens 
Eighty consecutive bladder washing specimens from 13 patients with high risk 
superficial TCC who underwent clinical progression to invasive disease (pT>2) and 13 
patients (age/sex/follow-up matched) who did not experience progression were 
analyzed. As a control group 35 bladder washings from 11 patients with a low risk 
karyometric score and no progression of disease were analyzed. The bladder washings 
were obtained from a large prospective study in which bladder washings of patients 
were collected for quantitative karyometric analysis (228). If patients were diagnosed 
with superficial TCC, bladder washings were collected and analyzed with three to 
twelve months intervals. All patients were designated as high risk superficial TCC on 
basis of quantitative karyometric analysis (228) and intermediate or high risk by 
calculating their prognostic index score based on rumor stage, multicentricity, recurrence 
rate and number of bladder areas involved (101). All patients received optimal 
intravesical therapy (e.g. Bacillus Calmette-Guerin instillations) as soon as they were 
considered to have a high risk superficial bladder tumor. Clinical and pathological data 
for the high risk patients are summarized in Table 1. 
The bladder was washed with 50cc saline that was immediately mixed with an equal 
volume Carbowax (50% ethanol, 2% polyethyleneglycol (PEG 1500)) for fixation. After 
centrifugation, the supernatant was decanted and the pellet resuspended in 3 ml of 
Carbowax and stored at -20°C. 
For DNA isolation 150 μΐ of bladder washing material was centrifuged for 5 minutes at 
13000 rpm. After decanting the supernatant, the pellet was washed two times with a 
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mixture of acetone/methanol (1 1) Subsequently, the cells were lysed in 50 μΐ lysis 
buffer (10 mM TnsHCl pH 8 8, 400 mM NaCl, 2 mM EDTA, 0 45% Tween 20"" and 
0 45% Nonidet P40) with 0 5 μ^μΐ proteinase K, for 1 hour at 60°C Proteinase К was 
inactivated by boiling the sample for 5 minutes 
PCR-SSCP 
PCR-SSCP analysis was performed to investigate p53 mutations in exons 5 through 9 
(160) Exon 8 and 9 were amplified together The intron primers tor amplification were 
5S (5'-tca-ctt-gtg-ccc-tga-ctt-3'), 5AS (5'-gag-gaa-tca-gag-gcc-tgg-3'), 6S (5'-gag-acg-
aca- ggg-ctg-gtt-3'), 6AS (5'-gag-acc-cca-gtt-gca-aac-3'), 7S (5'-cca-agg-cgc-act-ggc-ctc-
3'), 7AS (5'-gcg-gca-agc-aga-ggc-tgg-3'), 8/9S (5'-cct-tac-tgc-ctc-ttg-ctt-c-3'), 8/9AS (5'-
aaa-ctt-tcc-act-tga-taa-3') 
A 2 μΐ aliquot of bladder washing DNA solution was subjected to 40 cycles of PCR, 0 5 
minutes at 95°C, 2 minutes at 55°C and 1 3 minutes at 72°C 
Exons 5, 6, 8/9 were amplified in 50 μΐ containing 50 mM KCl, 10 mM Tns-HCL (pH 
8 8), 1 75 mM MgCl2, 250 μΜ deoxynucleotide triphosphates 10 pmol of each primer, 
3 μΰ α P-dATP and 1 5 units of Taq polymerase (Perkin Elmer/Cetus, Norwalk, 
Connecticut, USA) Exon 7 was amplified in the same buffer containing 1 4 mM 
magnesium chloride 
Five microliters of the PCR product were diluted in 15 μΐ of loading buffer (96% 
formamidc, 20 mM EDTA, 0 05% bromophenol blue and xylene cyanol), boiled for 3 
minutes and then quenched (10 min ) on ice before loading (2 μΐ per lane) Each sample 
was applied to a 5% polyacrylamide/Tns-borate EDTA (0 5x) gel with 10% (v/v) 
glycerol Subsequently, electrophoresis was performed at room temperature for 16 hours 
at 6W (exon 8/9) and 5W (exon 5, 6, 7) respectively 
Sequence analysis 
Sequencing of the double stranded PCR products that showed a mobility shift on the 
SSCP gel was performed as previously described (109) Direct sequencing of the 
amplified product was performed in cases where the intensity of the mutant DNA 
fragment was >50% of the wild-type DNA fragment Whenever the intensity of the 
shifted DNA fragment was <50%, we excised the mutant fragment from the 
Polyacrylamide gel and the gel piece was immersed in 100 μΐ of a 20 mM Tris (pH 8 0) 
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1 mM EDTA solution and heated at 80°C for 15 minutes. The extract was briefly 
vortexed and incubated overnight at 4°C. After brief centrifugation 10 μΐ of the 
supernatant was subjected to PCR reamplification for 45 cycles. 
Before sequencing, the amplified PCR products were subjected to electrophoresis on an 
2% low-melt agarose gel and further purified with the Magic Preps"" DNA purification 
system (Promega, Madison, WI, USA). For sequencing in the AmpliCycle1"1 system 
(Perkin Elmer/Cetus, Norwalk, Connecticut, USA) we used internal primers: 5S (5'-tgt-
ctc-ctt-cct-ctt-cct-ac-3'X 6S (5'-ggt-ccc-cag-gcc-tct-gal-tc-3'), 7S (5'-tct-tgg-gcc-tgt-gtt-
glc-tc-3'), 8S (5'-ttg-ctt-ctc-ttt-lcc-tat-cc-3'), 9S (5'-cac-ctt-tcc-ttg-cct-ctt-tc-3'). 
Electrophoresis was performed on a 6% Polyacrylamide (19:1) gel containing 7M urea. 
Table 1. Clinical and pathological* data correlating with bladder washings of high risk 
superficial bladder cancer patients, respectively with and without progression of disease. 
Stage 
Ta 
Ta + CIS 
T1 
T1 +CIS 
CIS 
Grade 
1 
2 
3 
Age (mean in years) 
Sex ratio 
follow-up 
(mean in 
(range in 
(M/F) 
months) 
months) 
Progression (n) 
6 
-
3 
2 
2 
1 
4 
6 
69.1 
11/2 
50.5 
(13-91) 
No progression in) 
5 
1 
4 
2 
1 
-
6 
6 
65 
11/2 
53.9 
(31-83) 
Pathological data at the moment of first quanticyt sample, in case no pathological data are 
present previous diagnosis is taken into account, M, male, F, female 
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Results 
SSCP analysis 
PCR-SSCP analysis of exons 5 through 9 was performed on DNA isolated from bladder 
washings. Figure 1A shows in lane 5 and 6, next to the wild type DNA fragments 
corresponding to exon 5, a clear mobility shift. The intensity of the wild type DNA 
fragments compared to the mutated fragment could most likely be explained by the 
presence of normal cells (wild type p53 phenotype) in the bladder washing. Figure IB 
shows in lane 6, a clear mobility shift of the DNA fragment corresponding to exons 8/9 
that were amplified together. The intensity of the mutated DNA fragment implies that in 
most cells in this bladder washing the p53 gene is mutated. 
1 2 3 4 5 6 7 8 9 10 
1 2 3 4 5 6 7 
• · · 
Figure 1A. 
PCR-SSCP analysis of exon 6 in bladder 
washings of patients with superficial TCC. 
Mobility shifts are observed in lanes 5 and 6. 
Figure 1B. 
PCR-SSCP analysis of exon 8/9 in bladder 
washings of patients with superficial ТСС. A 
mobility shift is observed in lane 6. 
Figure 1С shows the sequence analysis result of the antisense strand of exon 6 (case #3); 
a transition from a Τ to а С is shown at codon 205 resulting in a change of a tyrosine to a 
lysine. Mobility shifts were observed in eight patients (Table 2). Mutations were found 
once in exon 5, two times in exon 6 and four times in exon 8. In one patient (case #1) 
two different mutations were detected in the consecutive bladder washings analyzed. A 
different mobility shift was observed by SSCP-analysis, in concordance with the 
different nucleotide change. We found four transitions; twice a G to A, once a A to G 
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and three transversions; a Τ to G and twice a G to С In case #5 the known 
polymorphism in codon 213 of exon 6 (139) was detected. The identified point 
mutation, i.e. an A to G transversion did not result in an amino acid change (Table 2). 
case # 3 
Τ С О A 
τ 
с 
А 
т/с ^ 
А 
А 
А 
Figure 1С. Sequence analysis of the antisense strand of exon 6 (case #3); a mutation 
from Τ to С is shown at codon 205 resulting in a change of a tyrosine to a lysine. 
Correlation p53 mutation and progression of disease 
To assess the additional prognostic value of p53 mutations for superficial TCC indicated 
to be high risk on basis of quantitative karyometric analysis, p53 mutations were 
analyzed in bladder washings of 26 patients (Table 2a and b). p53 Mutations were found 
in 6 out of 13 patients (46%) with progressive superficial bladder cancer (Table 2a). One 
out of 13 patients (7.7%) with no progression of disease (23 month follow up) (Table 
2b) showed a p53 mutation. The positive predictive value of p53 mutations for 
progression of high risk superficial TCC was 86% (6/7). The observed negative 
predictive value was 63% (12/19). To assess when p53 mutations occur during the 
process of tumor progression, consecutive bladder washings from the same patient were 
analyzed. 
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Table 2. p53 Mutations analyzed (PCR-SSCP) in consecutive bladder washings of 
patients with superficial bladder cancer. 
A. Patients with progression of disease (high risk) 
Case no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Year" 
90 
92 
92 
93 
93 
90 
91 
91 
91 
92 
93 
94 
90 
91 
92 
92 
91 
91 
92 
93 
94 
94 
94 
91 
92 
92 
93 
93 
94 
94 
94 
94 
92 
94 
94 
91 
93 
93 
94 
95 
92 
94 
Stage/Grade' 
a/1 
2/3 
1/3 
1/2b, CIS 
2/2 
a/2 
a/2 
1/2b 
1/3, CIS 
4/3 
1/3, CIS 
>2/3 
CIS 
NR 
atypia 
4a/2-3 
CIS 
2/3 
NR 
NR 
CIS 
1/3, CIS 
4a/3 
NR 
1/3 
2/3 
1/3, CIS 
NR 
CIS' 
CIS' 
NR 
2/3 
NR 
NR 
>2 
a/2 
sq metasplasia 
(CT CIS + positive 
lymph nodes) 
1/3 
4/3 
a/2 
2/3 
p53 Mutation 
exon 8 
exon 8 
exon 5 
normal 
nd 
normal 
normal 
normal 
exon 6 
exon 6 
exon 8 
exon 8 
exon 6C 
exon 6 
exon 6 
exon 6 
exon 6 
normal" 
normal 
normal 
normal 
normal 
nd 
normal 
normal 
normal 
normal 
normal 
exon 8 
exon 8 
normal 
normal 
normal 
normal 
normal 
normal 
nd 
normal 
normal 
normal 
nd 
Amino acid change 
codon 285 / GAG -> AAG / Glu -> Lys 
codon 281 / G AC -> С AC / Asp -> His 
nd 
codon 205 / TAT -> TGT / Tyr -> Lys 
codon 205 / TAT -> TGT / Tyr -> Lys 
codon 273 / CGT -> CAT / Arg -> His 
codon 273 / CGT -> CAT / Arg -> His 
codon 213 / CGA -> CGG 1 Arg -> Arg 
nd 
codon 21 3 / CGA -> CGG / Arg -> Arg 
codon 213 / CGA -> CGG 1 Arg -> Arg 
codon 194 / CTT -> CGT / Leu -> Arg 
nd 
codon 280 / AGA -> AAA / Arg -> Lys 
A
 year of bladder wash sampling, " of concomitant tumors, c known polymorphism (1 39), 
D
 not representative sample; CT, cystectomy; NR, no abnormalities seen by cytoscopy, 
nd, not determined, sq, squamous; CIS', suspicion for presence of CIS 
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Table 2. 
В Patients without progression of disease (high risk). 
Case no 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
Year' 
91 
92 
93 
94 
94 
91 
91 
92 
94 
90 
91 
92 
90 
91 
93 
94 
94 
90 
91 
93 
91 
93 
90 
91 
91 
92 
94 
92 
92 
92 
93 
93 
92 
92 
93 
94 
92 
94 
94 
92 
93 
94 
94 
Stage/Grade" 
1/3 
NR 
NR 
a/3, CIS 
NR 
recurrences 
recurrences 
a/1 
papillary multiple 
a/2b 
a/3, CIS 
1/3 
a/2a 
1/3 
a/2b 
a/2a, CIS 
papillary multiple 
a/2b 
NR 
1/2, CIS 
a/2a 
NR 
1/2b 
1/2b 
1/2b, CIS 
NR 
a/3 
1/2, CIS 
1/2, CIS 
a/3, CIS 
NR 
NR 
NR 
tumor 
NR 
NR 
NR 
NR 
papillary multiple 
NR 
NR 
NR 
papillary lesion 
p53 Mutation 
normal 
normal 
exon 8 
exon 8 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
Amino acid change 
codon 280 / AGA -> АСА / Arg -> Thr 
codon 280 / AGA -> АСА / Arg -> Thr 
4
 year of bladder wash sampling, s of concomitant tumors sample, 
NR, no abnormalities seen by cytoscopy 
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The occurrence of a p53 mutation in the course the disease in individual patients (n=7) is 
summarized in Figure 2. Out of these 7 patients, 6 showed progression. It is noteworthy 
that the p53 mutations were detected in bladder washings with a mean of 8 months 
(range 4-14) before progression to invasive disease. From two patients (case #2 and #4) 
no bladder washings were available from the first period of disease (resp., 58 and 6 
months). The first analyzed sample showed in both cases a mutation, followed by 
progression to invasive disease after respectively 9 and 5 months. In two patients (case 
#3 and #9) first the wild type genotype was found. Within 12 and 9 months respectively, 
a mutation was detected followed by the occurrence of an invasive tumor 7 and 9 
months later. In two patients (case #1 and #6) mutated p53 was detected at first 
diagnosis followed by progression to invasive disease after respectively 14 and 4 
months. In only one patient (case #15) a p53 mutation was not followed by progression 
to invasive disease; 2 years after diagnosis the mutated p53 was observed in the bladder 
washings, but until now (23 months later) no progression to invasive disease has been 
observed. The histologic data of the tumors resected from the bladder at the moment of 
the first appearance of a p53 mutation in the bladder washings are shown in Table 2. 
case tf 
1 
0 14 yy „ . 56 
MUT INV A 
2 
0 yy 68 69 ». 84 
•> MUT INV A 
3 
О 12 1Э _ X 22 
WT MUT INV D 
4 
0 6 11 X 19 
' MUT INV О 
6 
О 4 . у/- «^ 48 
MUT INV A 
9 
0 _ 2 11 20 X 25 
' WT MUT INV D 
15 
0 17 yy- 39 •». 62 
~* WT MUT A 
Figure 2. Timing p53 mutations m tumor progression cascade. 0 = first diagnosis; ~> = 
no bladder wash available; WT = wild type p53; MUT = mutated p53; INV = occurrence 
of invasive tumor (pT>2); A = alive; D = dead; time in months. 
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Discussion 
Compared to superficial TCC, invasive disease constitutes an considerably greater threat 
to the patient's health. Since 10-25% of superficial TCC progress to invasive disease 
(74,101), prediction of tumor progression is an important issue in bladder cancer 
management. Multifocal occurrence of bladder tumors suggests a general disease of the 
urothelium rather than a localized process. In this respect both voided urine and bladder 
washings have the advantage over histological biopsies in that they reflect the general 
status of the bladder mucosa since cells from the entire bladder are sampled. In 1945 
Papanicolaou had already shown that exfoliation of tumor cells in the urine is a powerful 
diagnostic tool for detection and grading of patients with TCC of the bladder ( 164). 
However, the sensitivity for delecting low grade tumors and the reproducibility of this 
cytological grading system is disturbingly low (196). Since bladder washings enable the 
harvest of more and better preserved material compared to voided urine (1,255), van der 
Poel and coworkers applied quantitative karyometric analysis (2c Deviation Index and 
nuclear shape) to bladder washings in order to increase both the reproducibility and 
sensitivity of the cytological analysis (228). The sensitivity for detecting low grade 
tumors increased substantially by using this analysis and additionally 86% of all tumor 
recurrences were preceded by a cytoscopically negative sample with positive 
karyometric score (Van der Poel et al., unpublished data). Notwithstanding this 
improvement, we attempted to enhance the clinical usefulness of this screening 
procedure by adding an additional marker. Although mutations in the p53 tumor 
suppressor gene frequently occur in bladder cancer and correlate with grade and stage 
(64,199,233,207), until now it has remained unclear exactly when during the tumor 
progression process p53 mutations occur. We choose to analyze mutations in the p53 
gene directly because of the more objective nature of this analysis compared to 
immunohistochemical studies. Variation between immunohistochemical studies caused 
by different antibodies and scoring systems (5,233) can make comparison difficult. For 
superficial bladder cancer a clear prognostic significance for p53 overexpression has 
been shown (47,181,182,194), however conflicting data were also reported (66,126). 
Despite the fact that p53 accumulation and mutation of the p53 gene are well correlated, 
in 20-30% of the cases they appear to be separate events (46,163,234), so there is no 
obligate causal relationship between mutation and protein overexpression. 
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Last year Hruban and coworkers showed that in the case report of Hubert H. Humphrey, 
a p53 mutation was present in a urine-cytology specimen 9 years before an infiltrating 
carcinoma of the bladder occurred (93). It should be noted that in this study the mutation 
was first analyzed in the histological tissue and then retrospectively the known mutation 
was detected in the urine specimen. Although the method used is very sensitive it has 
limited clinical relevance. In our study we used PCR-SSCP analysis and applied it 
directly to bladder washings in order to define when p53 mutations take place during the 
tumor progression process and moreover assess the additional prognostic value of p53 
mutation analysis for patients who were indicated to be at high risk for recurrences on 
basis of their quantitative karyometric analyses (228). 
In the present study we found p53 mutations in the samples of all patients prior to 
progression, with a mean of approximately 8 months (range 4-14). Of two patients (case 
#2 and #4) however, in the earlier course of their disease, no bladder washings were 
done. Case #4 was diagnosed 6 months before the first mutation was found so the period 
between the first p53 mutation and progression could have been at most, 11 months. 
Case #2 could have had the mutation much longer since we have no bladder washing 
samples from the first 58 months of disease. In only one patient (case #15) the 
appearance of a p53 mutation has not yet been followed by progression to invasive 
disease (23 month follow up). A drawback of analyzing p53 mutations in bladder 
washings is illustrated by the absence or low number of mutated p53 cells in the bladder 
washing specimens of case #6 and #9 in the presence of a concomitant invasive tumor. 
The existence of the p53 mutation in the invasive tumor was confirmed by analyzing the 
histological material (data not shown). It is obvious that relevant cells are not sampled 
and a mutation can be missed if a tumor grows into the bladder wall or is covered by 
normal urothelium. 
We observed identical p53 mutations in the consecutive bladder washings of four 
patients, which in favor with the theory of the clonal origin of bladder tumors (200). 
However, there was one exception, case #1, in which we found different p53 mutations 
in the individual bladder washings, implicating that the tumors resulted from two 
independent transforming events. These results are in agreement with the observed 
different p53 gene mutations in CIS or dysplasia and consecutive invasive tumors in two 
patients in a previous study (207). 
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Six out of 13 patients that clinically progressed (to pT>2) showed a p53 mutation in one 
or more of their bladder washings. In the control group (no progression) only 1 out of 13 
patients showed a p53 mutation. In the group of superficial TCC patients at risk for 
recurrence, the occurrence of a p53 mutation has a positive predictive value for 
progression to invasive disease of 86%. 
We observed a negative predictive value of 63%. This low negative predictive value 
implicates that, although a p53 mutation indicates a malignant potential for the tumor, 
the absence of a p53 mutation does not guarantee a good prognosis, which we have 
already demonstrated for invasive bladder tumors (233). Other mechanisms as well can 
lead to tumor progression and these may override or bypass the function of p53. For 
example, overexpression of the epidermal growth factor receptor (EGFR) in patients 
with superficial TCC has been shown to correlate with several malignant features and a 
worse prognosis (127,154,155). E-cadherin is a potential candidate with predictive value 
for progression of superficial TCC, but its clinical usefulness remains to be assessed 
(18,162). Inactivation of wild type p53 by complexing with the cellular proto-oncogene 
MDM2 could also disrupt p53 function (148). It has also been recently shown that 
MDM2 enhances proliferation by stimulating the S-phase inducing transcription factor 
E2F/DP1 (136). Both mechanisms could participate in progression of disease. For 
bladder cancer it has been shown that MDM2 overexpression is strongly correlated with 
low-stage, low-grade tumors and that a strong association with p53 overexpression 
exists. The precise clinical relevance of MDM2 overexpression in bladder cancer 
remains to be proven (119). 
In spite of the positive predictive value of 86%, the occurrence of a p53 mutation is not 
an absolute sign for progression of disease. Whenever a high karyometric score is 
observed in a bladder washing of a superficial TCC patient this is an indication for both 
a careful follow up (at least every three months) and p53 mutation analysis. As a control 
experiment we also analyzed thirty-five bladder washings with a low karyometric score 
for the presence of a p53 mutation; in this group no p53 mutations were detected (data 
not shown). The occurrence of all p53 mutations in the group of patients with a high 
2cDI value (abnormal DNA content) suggests a link between p53 dysfunction and 
genomic instability (213,229,233). The combination of a high karyometric score and a 
p53 mutation identifies patients with a high probability of progression to invasive 
disease, within a relatively short time period (approximately 8 months). However, 54% 
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of the high risk patients without a demonstrable p53 mutation progress to invasive 
disease. Summarizing these data, it is obvious that more prognostic markers are needed 
to increase not only the positive predictive value but especially the negative predictive 
value of this screening procedure. Our choice to study p53 mutations by SSCP, does not 
exclude the usefulness of p53 immunohistochemistry on bladder washings, especially 
since it is more accessible as a diagnostic tool. We are currently studying the predictive 
value of p53 overexpression analyzed by immunohistochemistry in bladder washings for 
progression of superficial TCC. 
In conclusion, for a group of superficial TCC patients indicated to be high risk based on 
karyometry (228), the occurrence of a p53 mutation has positive predictive value for 
disease progression. Moreover, since p53 mutations were found in samples prior to 
documented progression their presence could identify patients who need a change in 
their treatment strategy in order to prevent progression to invasive disease. The clinical 
usefulness of p53 mutations as a marker with additional predictive value should now be 
assessed in a large prospective study. 
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Chapter 5 
Comparative analysis of p53 mutations in bladder washings 
and histological specimens. 
Jacqueline AM Vet1, PhD, Daphne Hessels1, MS, Salvatore AE, Marras1, MS, Christina A van 
de Kaa2, MD, Henk G van der Poel', MD, Rob J Michalides3, PhD, Frans MJ Debruyne1, 
MD, Jack A Schalken', PhD 
Abstract 
Bladder washings have the advantage over histological specimens in that they reflect the general 
status of the urothelium and since it is a simple outpatient procedure, patients can be monitored 
more carefully Mutations in the tumor suppressor gene p53, analyzed in bladder washings, 
have been reported to be of significant prognostic value for the progression of superficial 
bladder cancer to invasive disease To determine the actual value of bladder washing specimens 
to assess the p53 status of histological specimens, we analyzed bladder washings and the 
synchronous tumors of 15 patients for the presence of p53 mutations using Polymerase Cham 
Reaction-Single Strand Conformation Polymorphism (PCR-SSCP) A significant correlation 
(p<0 05, Fischer Exact, two-tail test) between the p53 status of bladder washings and 
histological specimens was observed if these were compared among the specimens of a single 
patient Overall, in 2 patients, the mutation present in the tumors was not detected in the bladder 
washings and in one patient the mutation in the bladder washing was not detected in the 
histological specimens These conflicting results between bladder washings and histological 
specimens could partly be explained by the architecture of the tumors The observed specificity 
of 86% and sensitivity of 75% emphasizes that although there is a good correlation between the 
two methods in a number of cases they are complementary to one another From these findings 
we conclude that the analysis of p53 mutations in consecutive bladder washings of a patient 
does generally reflect the p53 status of the synchronous tumors 
Departments of Urology' and Pathology , University hospital Nijmegen, Nijmegen and the 
Department of tumorbiology, The Netherlands Cancer Institute , Amsterdam, The Netherlands 
This work was supported by grants from the Dutch Cancer Society (NUKC9102 and 
NUKC9251) Submitted for publication 
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Introduction 
Bladder cancer is, with an annual incidence of 20 cases per 100.000, the fifth most 
prevalent cancer in the western male population. In women a lower incidence of five 
cases per 100.00 is observed (173). Superficial TCC, which accounts for 80% of all 
newly diagnosed TCCs, in general has a good prognosis. However, 10-25% of these 
tumors progress to invasive disease (74,101). To identify patients at risk for progression 
to invasive disease, reliable prognostic markers are urgently needed. 
Multifocal occurrence of bladder tumors is consistent with field disease of the 
urothelium rather than a focal process. In this respect bladder washings have an 
advantage over histological biopsies in that they reflect the general status of the entire 
urothelium of the bladder. In a large prospective study in our hospital, bladder washings 
were studied by quantitative karyometric analysis in which two nuclear features, 2c 
Deviation Index and nuclear shape were analyzed (228) . This karyometric analysis on 
exfoliated cells in bladder washings resulted in a substantial increase of the 
reproducibility and sensitivity of the standard cytological analysis. Moreover, it offers 
additional prognostic information to classical factors (unpublished observations). In a 
previous study we attempted to enhance the clinical usefulness of this procedure to 
predict progression, by adding an additional prognostic marker: the tumor suppressor 
gene p53. The p53 gene is located on chromosome 17p 13.1 and encodes a nuclear 
phospoprotein involved in the maintenance of DNA integrity and is the most common 
mutated gene in human malignant tumors (87,117). Our findings indicate that for a 
group of superficial TCC patients at risk for recurrence as indicated by karyometric 
analysis (228), the occurrence of a p53 mutation detected in their bladder washings has a 
positive predictive value of 86% for the progression to invasive disease (unpublished 
observations). In order to determine the actual value of bladder washing specimens to 
asses the p53 status of histological specimens, we analyzed the bladder washings and 
their synchronous tumors of 15 patients for the presence of p53 mutations. 
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Material and Methods 
Specimens 
Histological samples 
Sixteen paraffin-embedded superficial bladder carcinomas (pTa-pTl), three superficial 
carcinomas with associated carcinoma in situ (CIS), eight muscle-invasive carcinomas 
(pT>2), two CIS, 3 metastases obtained from 15 patients with high risk superficial TCC 
were used for PCR-SSCP analysis. All patients were indicated to be at high risk for 
superficial TCC progression on the basis of quantitative karyometric analysis (228) and 
as intermediate or high risk by calculating their prognostic index score based on tumor 
stage, multicentricity, recurrence rate and number of bladder areas involved (101). All 
patients received optimal intravesical therapy (e.g. Bacillus Calmete-Guerin instillations) 
as soon as they were found to have a high risk superficial bladder tumor. 
For DNA isolation four 20 μιη sections of paraffin embedded tissue were used. Using an 
adjacent 5 μιη H/E stained section as a guide, the tissue of interest (> 70% tumor cells) 
was dissected from the paraffin section and transferred to an eppendorf tube. Depending 
on the amount of tissue 100-500 μΐ lysis buffer was added. After vortexing the tube was 
briefly centrifuged. For each 100 μΐ lysis buffer (10 mM TrisHCl pH 8.8, 400 mM NaCl, 
2 mM EDTA, 0.45% Tween 20m and 0.45% Nonidet P40) 5 μΐ proteinase К (10 mg/ml) 
was added. The tube was gently mixed and incubated for 1 hour at 60 °C. 
The proteinase К was inactivated by boiling for 5 minutes. After brief centrifugation, the 
DNA suspension was removed from the remaining paraffin and transferred to a new 
tube. A phenol extraction and an alcohol precipitation were performed and the samples 
were resuspended in one-half of the original volume. A 2.5 - 5 μΐ aliquot of DNA 
solution, depending on the original amount of tissue, was subjected to 45 cycles of PCR. 
Bladder washing samples 
Twenty-six bladder washing specimens from the same 15 patients were analyzed for p53 
mutations. DNA isolation was performed as described in chapter 4. 
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PCR-SSCP and sequences analysis 
PCR-SSCP and sequence analysis were performed as described in chapter 4. 
p53 immunohistochemistry 
Paraffin embedded tissue of 29 bladder tumors and 3 metastases were studied for the 
occurrence of p53 overexpression. For immunohistochemistry 5 μτη sections were 
deparaffinized, rehydrated and covered with citrate buffer (10 mM, pH6) and underwent 
a microwave-retrieval treatment (setting at 450W) for 15 minutes (75). The slides were 
then washed twice with PBS, and were rinsed thoroughly with PBS between each of the 
following steps. The sections were first blocked with undiluted rabbit serum, for 10 
minutes at 37°C. The sections were then incubated overnight with a 1:400 dilution of 
DO-7 (DAKO) at 4°C. Subsequently the sections were incubated with biotinylated rabbit 
anti-mouse (1:1000 in PBS/1% BSA) (DAKO) for 30 minutes at room temperature. 
Preformed peroxidase-conjugated streptavidin-biotin complex (DAKO) was then 
applied for 30 minutes at room temperature, and peroxidase was demonstrated by 
applying 0.05% 3,3'-Diaminobenzidine containing 0.6% hydrogen peroxide for 5 
minutes. The sections were then thoroughly washed in water and nuclei were lightly 
counterstained with hematoxylin. The pattern of nuclear overexpression was classified in 
four categories by estimating the percentage of stained tumor cells: -, no positive cells; 
+, 1 to 10% positive tumor cells; ++, 10 to 50% positive tumor cells and +++, >50% 
positive tumor cells. 
Statistical analysis 
The Chi-square test (with Yates correction if relevant) and the Fischer Exact test were 
used to demonstrate statistical difference between groups. 
Results 
p53 mutations in histological specimens 
Thirty two histological specimens from 15 patients were analyzed by PCR-SSCP. 
Mutations were found in 7 out of 8 (87.5%) muscle-invasive tumors, 6/21 (28.5%) 
superficial tumors (and associated CIS) and in one of the three metastases studied (Table 
1). Mutations were found four times in exon 6 and eleven times in exon 8. 
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Table 1. Comparison of p53 mutations analyzed (PCR-SSCP) in bladder washings and 
concomitant histological specimens. 
Case 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Year 
051290 
140292 
091292 
160393 
101193 
181290 
081191 
311291 
150792 
221093 
090594 
090594 
060892 
230891 
111291 
021287 
270592 
150992 
301192 
281194 
020195 
020195 
260690 
040393 
230889 
061192 
270691 
100192 
081093 
011290 
061191 
161091 
Histologi 
Stage/ 
Grade 
a/1 
2/3 
1/3 
1/2b 
1/2 
a/2 
1/2b 
1/3.CIS 
>2/3 
1/3 
4/3 
(meta) 
4/2 b 
CIS 
>2/3 
a/1 
1/3 
2/3 
(meta) 
2/3 
4/3 
(meta) 
1/3.CIS 
CIS 
a/2b 
a/2b 
a/3 
1/3 
a/2b 
a/2b 
a/2b 
1/2b,CIS 
cai material 
Mutation 
normal 
exon 8 
normal 
normal 
normal 
normal 
normal 
exon 6 
exon 6 
exon 8 
exon 8 
exon 8 
exon 6P 
exon 6 
exon 6 
exon 8 
exon 8 
exon 8 
normal 
nd 
exon 8 
exon 8 
normal 
normal 
nd 
exon 8 
nd 
normal 
normal 
normal 
normal 
normal 
normal 
normal 
exon 8 
nd 
nd 
p53 Alterations 
Immuno-
positivity* 
+ + 
+ + 
+ 
+ 
+ 
+ + + 
+ + + 
+ + 
+ + 
+ + 
-
+ + 
+ 
-
+ + 
+ + 
+ 
+ + 
+ 
+ + 
+ + 
+ + + 
+ + 
+ + 
+ 
-
-
-
-
+ + + 
Year 
051290 
140292 
011292 
160392 
210993 
181290 
071191 
301291 
150792 
131093 
290394 
011092 
230891 
101291 
nd 
200592 
140992 
180594 
161194 
211191 
290993 
211092 
270691 
290993 
011290 
051191 
151091 
221092 
190892 
Mutation 
exon 8 
exon 8 
exon 5 
nd 
normal 
normal 
normal 
exon 6 
exon 6 
exon 8 
exon 8 
exon 6 p 
exon 6 
* 
normal 
normal 
exon 8 
normal 
nd 
nd 
normal 
nd 
exon 8 
nd 
normal 
normal 
nd 
normal 
normal 
normal 
normal 
normal 
normal 
Bladder washings 
Amino acid change8 
codon 285 / GAG -> AAG / Glu -> Lys 
codon 281 / GAG -> G AC / Glu -> Asp 
codon 205 / TAT -> TGT / 7ул-> Lys 
codon 205 / TAT -> TGT / Tyr-> Lys 
codon 273 / CGT -> CAT / Arg -> His 
codon 273 / CGT -> CAT / Arg -> His 
codon 273 / CGT -> CAT / Arg -> His 
codon 213 / CGA -> CGG 1 Arg -^ Arg 
codon 194 / CTT -> CGT / Leu -• Arg 
codon 194 / CTT -> CGT / Leu -> Arg 
codon 280 / AGA -» AAA / Arg -> Lys 
codon 280 / AGA -> AAA / Arg -> Lys 
codon 280 / AGA -» AAA / Arg -> Lys 
nd 
codon 280 / AGA -> АСА / Arg -> Thr 
A
 number of positive cells:-, 0%; +, 1-10%, + + , 10-50%; + + + , > 50%; p polymorphism codon 213, 
mutations confirmed in both bladder washing and histological specimen (when both specimens were available). 
, not representative sample, nd, not determined. 
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In case #5 the previously described polymorphism in codon 213 of exon 6 (139) was 
detected. The identified nucleotide change, i.e. an A to G transversion did not result in 
an amino acid change (Table 1). 
p53 mutations in bladder washings 
Twenty-six bladder washings of 15 patients from this group were compared with the 
concomitant histological specimens. Mutations were found in 10/26 (38.5%) bladder 
washings (Table 1). 
Mutations were found once in exon 5, three times in exon 6 and six times in exon 8 
(Table 1). In case #5 again the known polymorphism in exon 6 was detected (139). 
Table 2. Relationship between the overall p53 status of bladaer washings and 
synchronous histologic specimen summarized for each individual patient. 
BW / p53mut 
BW / p53wt 
Total number 
Histo / p53mut 
6 
2 
8 
Histo / p53wt 
1 
6 
7 
Total number 
7 
8 
15 
Histo, histological specimen; BW, bladder washing; 
p53mut, mutated p53 gene; p53wt, normal p53 gene. 
Comparison p53 mutations in bladder washings and synchronous histological 
material. 
To investigate the usefulness of bladder washings to determine the p53 status of the 
synchronous tumors, we compared both specimens for these 15 patients (Table 1). 
If the results for each individual patient are summarized, the p53 analysis of the bladder 
washings and histological specimens showed a significant correlation (p<0.05, Fischer's 
exact test, two-tail) (Table 2). A specificity of 86% (6/7) and a sensitivity of 75% (6/8) 
was observed. Overall in two patients (case #7 and #15) the mutation found in the 
histological specimen could not be detected in one of the consecutive bladder washings 
and in one patient (case #2) the mutation observed in the bladder washing is not detected 
in any of the histological specimens analyzed. These conflicting results between 
histological specimens and bladder washings can partly be explained by the architecture 
of the tumors as is shown in Figure 1. Both the pTlG3 and the pT2G3 tumor of case #7 
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were covered by normal urothelium, as is clearly illustrated by the immunohis-
tochemical staining of these histological specimens (Figure 1A and IB). In case #15 the 
p53 overexpressing cells are present in a CIS lesion that is in contact with the luminal 
site, but the number of cells is very small (Figure 1С). The concomitant pTlG2b tumor 
is growing in brunns cell nests (Figure ID). In two out of the three metastases (case #7 
and #8) the mutation observed in the original tumor is not detected. The relatively small 
number of p53 overexpressing tumor cells in these metastases is the most likely 
explanation (Figure IE). The PCR-SSCP analysis of the other metastasis (case #4) 
revealed the same mutation as observed in the original tumor. As is shown in figure IF 
the relative amount of p53 overexpressing tumor cells in this metastasis is much higher 
compared to case #7 and #8. 
Individual comparison of bladder washings and their synchronous histological 
specimens revealed some additional discrepancies as is shown in Table 1. In case #1 the 
mutation in the first analyzed bladder washing was not found in the concomitant tumor. 
The next histological specimen, however, revealed a different mutation, that was 
confirmed in the concomitant bladder washing. In case #8 a mutation was found in the 
histological specimen but not in the concomitant bladder washing. However, the same 
mutation was found in a prior analyzed bladder washing. 
p53 immunohistochemistry 
We defined a tumor as p53 positive if more than 10% of the tumor cells showed p53 
overexpression. A significant correlation between p53 mutation and p53 overexpression 
is observed (p<0.01, chi-square = 7.18) (Table 1). However, 3 out of 15 tumors (20%) 
with a proven p53 mutation show no p53 overexpression, whereas of the 18 tumors with 
p53 overexpression 6 tumors (33%) have no identified p53 mutation. 
Comparison specific nature mutations confirmed by sequence analysis 
Sequence analysis revealed 9 transitions and 4 transversions (Table 1). Of the 5 patients 
of which sequence data were available from both the mutation observed in the bladder 
washing as well as in the synchronous tumor, 4 showed the same mutation. However, in 
one patient (case #1), different mutations were observed in the two bladder washings 
analyzed. 
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Figure 1: Immunohistochemical staining of p53 expression using p53 DO-7 monoclonal 
antibody. A. pT1G3 tumor of case # 7 ; B. pT2G3 tumor of case # 7 ; С CIS of case # 1 5 ; 
D. pT1G2b tumor of case # 1 5 ; E. lymph-node metastasis of case #8; F. lymph-node 
metastasis of case # 4 ; Original magnification: 100x (B), 200x (A,D,E,F) and 400x (C). 
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Discussion 
A significant problem in the management of patients with superficial TCC is the 
identification of those patients who are at risk for progression to invasive disease. Early 
identification could make a change in the treatment strategy possible when the disease is 
still confined to the bladder. In our institution the prognostic index score (based on stage, 
grade, multicentricity and number of bladder areas involved) (101) and the quantitative 
karyometric analysis of bladder washings (228) are used as prognostic factors. These 
markers are useful to stratify patients with superficial TCC into low or high risk 
categories. However, the morbidity associated with cystectomy, which at the moment is 
the only treatment to prevent progression to invasive disease, emphasizes the need for 
additional markers to increase both the specificity and sensitivity of this procedure to 
predict progression. In a previous study we showed the positive predictive value of p53 
mutation analysis in bladder washings for progression of high risk (101,228) superficial 
TCC (unpublished observations). We chose to use bladder washings, because it is a 
simple outpatient procedure and patients can be monitored more carefully. Moreover, 
since bladder cancer is hypothesized to be a field disease of the urothelium, bladder 
washings have the advantage of reflecting the status of the entire bladder mucosa. The 
use of bladder washings is preferred over urine specimens, since more representative and 
better preserved material is harvested (1,255). 
PCR-SSCP analysis of the p53 gene in our histological specimens revealed an 
association of p53 mutations with invasive tumors as was previously shown 
(64,199,233). The pre-selected nature of the tumors in this study explains the observed 
higher percentage p53 mutations in both the superficial as well as the invasive tumors. 
The importance of analyzing p53 mutations in bladder washings results from the 
possibility of preventing disease progression by increased surveillance. The clinical 
relevance of the analysis is due to the ability to detect a p53 mutation in the bladder 
washing before progression to invasive disease has occurred and not per se the absolute 
concordance between the p53 status of each histologic specimen and its paired bladder 
washing. We found a significant correlation (p<0.05, Fischer Exact test, two-tail) 
between the p53 status of bladder washings and histological specimens if these were 
compared among the specimens of a single patient. However some discrepancies were 
observed. In one patient (case #2) a mutation was observed in the bladder washing, but 
71 
p53 Mutations in bladder washings and synchronous tumors 
could not be detected in any of the histological specimens analyzed. The existence of 
minor lesions that have already acquired the mutant p53 status (207) but were too small 
to be observed by cystoscopy could explain the presence of mutated p53 cells in these 
bladder washings. This phenomenon emphasizes the advantage of bladder washings 
which makes analysis of cells from the entire bladder mucosa possible. In two patients 
(case #7 and #15) the observed mutation in the histological specimen(s) was not detected 
in any of the bladder washings analyzed. The absence of mutated cells in the bladder 
washings of patient #7 could be explained by the histologic composition of the tumors. 
Both tumors were clearly covered by 'normal' (no p53 overexpression) urothelium which 
most likely prevented the release of mutated p53 tumor cells into the bladder washing. 
Although the clear presence of CIS in patient #15 (all of the cells showed p53 
overexpression) would predict that mutated cells should be present in the bladder 
washing, most likely the number of cells was too small to detect the mutation. The 
concomitant pTlG2b tumor is growing in brunns cell nests, preventing the major part of 
the p53 overexpressing cells from releasing in the bladder washing. 
Individual comparison of the synchronous bladder washings and histological specimens 
showed some additional discrepancies. In one patient (case #8) the mutation detected in 
the histological specimen (pT2G3) was not found in the concurrent bladder washing, but 
was observed in a previous bladder washing. The invasive nature of the tumor could 
have prevented the release of the mutated cells into the bladder washing. In one patient 
(case # 1 ) a mutation was observed in the bladder washing but could not be detected in 
the synchronous tumor. The subsequently resected tumor (14 months later), showed a 
mutation. This mutation however differed from the first observed mutation in the 
bladder washing, but was identical to the mutation found in the concomitant bladder 
washing. This occurrence of different p53 gene mutations in bladder tumors of one 
patient has also been reported in two TCC patients in a previous study (207). The other 
four patients showed identical p53 mutations in the consecutive bladder washings and 
the synchronous tumors, which is in agreement with the theory of the clonal origin of 
bladder tumors (200). 
PCR-SSCP analysis using histologic specimens can despite microdissection of tumor 
give false-negative results caused by the presence of a relatively high percentage of 
normal cells as is shown in this study, by the high number of lymphocytes in two of the 
three metastases analyzed (247). Although the good concordance between p53 mutations 
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and p53 overexpression, in a substantial number of tumors discrepancies are observed, 
which is in agreement with previous studies (81,234,249). 
In conclusion, in two patients, the mutation present in the tumors was not detected in the 
bladder washings and in one patient the mutation in the bladder washing was not 
detected in the histologic specimens. The observed specificity of 86% and sensitivity of 
75% emphasizes that although there is a good correlation between the two methods in a 
number of cases they are complementary to one another. More regular examination of 
bladder washings for the presence of a p53 mutation could lead to early identification of 
patients who need a change in their treatment strategy (conservative to radical) and 
thereby potentially prevent disease progression. 
From these findings we conclude that the analysis of p53 mutations in consecutive 
bladder washings of a patient does generally reflect the p53 status of the synchronous 
tumors. We are currently assessing the clinical usefulness of p53 mutation analysis in 
bladder washings as a prognostic marker in a prospective study. 
Acknowledgment 
We would like to thank Mrs. Petra Kristel, Mrs. Anita Gemmink and Mr. Coos 
Diepenbrock for excellent technical assistance. 
73 
74 
Chapter 6 
Chapter 6 
Differential expression of ferritin Heavy chain in a rat 
Transitional Cell Carcinoma progression model. 
Jacqueline A M Vet, Reindert J A van Moorselaar, Frans M J Debruyne, and Jack A 
Schalken 
Abstract 
To identify molecular markers with predictive value for the progression of superficial bladder 
cancer we used the differential hybridization analysis approach Since primary tumor material 
is heterogeneously composed of subpopulations that are poorly characterized, we used in this 
study a rat progression model system that phenotypically and cytogenetically resembles human 
superficial bladder cancer In the differential hybridization analysis we compared the mRNA 
populations of low and high metastatic tumor lines We observed an overexpression of ferritin 
Heavy chain (ferritin H) in the tumor line with the lower metastatic capacity and better 
differentiated phenotype The exact clinical relevance for the differential expression of ferritin H 
in human bladder cancer remains to be determined 
Department of Urology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, 
The Netherlands This work was financially supported by a grant from the Dutch Cancer 
Society (NUKC9102). Submitted for publication 
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Introduction 
An important issue in the management of superficial transitional cell carcinoma (TCC) 
of the bladder is to identify those patients that are at risk for progression to invasive 
disease. Since primary tumor material is usually heterogeneously composed of 
subpopulations that are poorly characterized, it is not suitable to identify TCC 
progression markers. The identification of such parameters requires a tumor model 
system in which the different stages of tumor progression are represented. 
In this study a rat bladder tumor model system (RBT) is used that phenotypically and 
cytogenetically resembles human superficial TCC (230). In order to identify genes that 
are associated with the progression of superficial bladder cancer we applied the 
technique of differential hybridization analysis to compare the mRNA levels of the RBT 
323 with the RBT 157 line, two lines that differ in their metastatic capacity. Both tumor 
lines initially resembled grade 2 TCC. However, while the histological pattern of the 
RBT 157 remained essentially unchanged, the RBT 323 tumor progressed to a grade 3 
tumor in the third passage. The cDNA clones that detected differentially expressed genes 
were further evaluated for their relationship to the metastatic phenotype by means of 
Northern blot analyses of all the passages of the rat TCC progression model. The cDNA 
clones of interest were sequenced and the resulting nucleotide sequences were compared 
to nucleotide database to search for homology with known genes. 
Materials and methods 
Tumor specimens 
Tumor material from a rat bladder tumor model system (RBT) (230) was used in this 
study (Table 1). Transplant passage #10 of the highly metastatic line RBT 323 and 
passage #1 of the moderate metastatic line RBT 157 were used for the differential 
hybridization experiments. In order to check the relevance of the selected clones 
passages 1, 2, 8, 9, 15 and 16 of the RBT 323 line and passage 1 through 6 of the RBT 
157 line were used. 
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Table 1 . Growth characteristics of rat bladder tumor lines. 
Tumor passage 
Passage 1 
Passage 2 
Passage 3 
Passage 4 
Passage 5 
Passage 6 
Passage θ 
Passage 10 
Passage 12 
Passage 13 
Passage 15 
Passage 1 
Passage 2 
Passage 3 
Passage 4 
Passage 6 
Tumor doubling time* 
ND 
ND 
13.4 (1.4) 
11.8 (1.2) 
5.9 (1.0) 
5.7 (0.3) 
4.4(0.1) 
3.8 (0.2) 
3.7 (0.2) 
4.2 (0.3) 
3.3 (0.3) 
4.3 (0.3) 
ND 
11.2 (0.8) 
ND 
10.5 (1.1) 
8.2 (0.3) 
9.5 (1.8) 
Metastases8 
0/1 
0/6 
0/8 
1/10 
0/9 
3/7 
11/13 
15/15 
9/9 
19/22 
6/6 
5/6 
0/1 
0/4 
1/7 
2/9 
5/8 
2/6 
A
 Tumor doubling time in days, standard error of the mean in brackets. * Number 
of rats with lung metastases/total number of rats implanted with respective 
tumor passage. ND, not determined. [RJA van Moorselaar et al.(230)] 
Construction of cDNA libraries 
A directionally cloned cDNA library was constructed using polyadenylated cytoplasmic 
RNA from the highly metastatic RBT323 line, passage #10. Poly(A+)-RNA (5 μg) was 
fractionated from total RNA by oligo(dT)-cellulose chromatography and total RNA was 
isolated using the lithium chloride/urea procedure (4). First strand cDNA was 
synthesized by using an oligo(dT) primer-adaptor (Promega) containing a NOT-1 site 5' 
to the oligo(dT) tail. Second strand cDNA synthesis was performed using the procedures 
described by Gubler and Hofman (76). The cDNA was blunt ended by using T4-DNA 
polymerase (10 U). After purification using micro collodion bags (Sartorius GmbH), 
EcoRl linkers (1 μg, Stratagene) were ligated to the blunt ended cDNA by means of T4-
DNA ligase, followed by digestion with NOT-1 and Eco-Rl restriction endonucleases. 
The digested linkers were separated from the cDNA by means of PurElute"11 agarose gel 
electrophoresis (Invitrogen) and the cDNAs with the desired size range (0.5-10 kB) were 
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isolated from the agarose. Electroelution of the cDNA from the agarose was performed 
using the Geneluter"1 electroelution system (Invitrogen). Subsequently the ds cDNA was 
ligated in the Lambda Zap-II cloning vector (Stratagene), inserted into the phage 
particles using Promega Packagene Lambda DNA Packaging System and transformed to 
XL-1 Blue E. coli bacteria. 
Differential screening of the cDNA library 
For the differential screening of the RBT 323/10 cDNA library, 36.000 recombinant 
phages were plated. After overnight incubation, 4 replicas of each plate were taken on 
nitrocellulose by incubation during 1, 3, 10 and 30 minutes respectively. The filters were 
next lysed according to Sambrook et al. (176). Hybridization was performed according 
to Hanahan and Meselson (82) in 40% formamide at 42°C during 60 hours. For the 
differential screening, probes representative for the RBT 323/pass.l0 and RBT 
157/pass.l mRNA populations were prepared by random prime labeling (53) of first 
strand cDNA. For hybridization of the filters, LIO6 dpm/ml hybridization solution was 
used. The replica's 1 and 10 minutes were hybridized with probe derived from the RBT 
157/pass.l and the replica's 3 and 30 minutes were hybridized with probe derived from 
the RBT 323/pass.l0. The blots were washed according to Hanahan and Meselson (82). 
The filters were exposed for autoradiography during three days. Extensive comparison 
of the autoradiograms resulted in selection of differentially expressed clones. 
Phagemid isolation 
Putative differential expressed cDNA clones were purified and phagemids were isolated 
according to the Stratagene protocol. 
Northern blot analysis. 
For the northern blot analysis, 10 micrograms of total RNA was glyoxylated, size 
fractionated on 1% agarose gels and transferred to Hybond-N+ nylon membranes 
(Amersham). Probes were made of the differentially expressed cDNA clones, obtained 
from small scale plasmid isolations or of purified inserts of the cDNA clones, by random 
prime labeling reactions (53). Hybridization experiments were performed according to 
Church and Gilbert (30). 
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Sequence analysis and computer analysis 
Sequence analysis was performed with the Sequenase Version 2.0 System (United States 
Biochemical). M13 and reverse primers were used allowing sequence analysis from both 
ends of the clones. Computer assisted comparison studies of the sequences were 
performed with the EMBL and Genbank nucleotide sequence databases. 
Results 
Differential screening 
A cDNA library was constructed from the mRNA of the highly metastatic line RBT 
323/passage 10. The complexity of the library was 4.3 χ IO5 recombinant clones and 
36.000 recombinant phages from the primary library were plated. Replica filters were 
differentially screened using radioactively labeled cDNA probes derived from poly-
A+RNA of the RBT 323/pass.l0 (high metastatic) and the RBT 157/pass.l (low 
metastatic). 
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Figure 1. Differential screening of the RBT 323/10 cDNA library. Replicas were hybridized 
to cDNA probes prepared using poly-A + -RNA from the RBT 157/1 line (A + C) or from the 
RBT 323/10 line (B + D). 
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Extensive comparison of the resulting autoradiograms (Figure 1) revealed 22 cDNA 
clones that seemed to be differentially expressed; 16 overexpressed in the RBT 323 line 
and 6 overexpressed in the RBT 157 line. These 22 selected cDNA clones were further 
evaluated using Northern blots containing 10 μg of RBT 157/1, RBT 323/1 and RBT 
323/10 RNA. The expression patterns of the most significant clones are shown in Figure 
2. 
pV11 pV13 pV16 pV19 
MW(kb) 
à ή 
Figure 2. Secondary screening of the selected cDNA clones on the passages RBT 157/1 
(1), RBT 323/1 (2) and RBT 323/10 (3). 10 //g of total RNA was glyoxylated, size 
fractionated on 1 % agarose gels and transferred to Hybond-N+ nylon membranes. Probes 
were made of the differentially expressed cDNA clones by random prime labeling reactions 
Expression pattern of pV13 
Clone pV13, is clearly overexpressed in RBT 157/1, the line with the lowest metastatic 
capacity. pV13 detects a single transcript of approximately 1.1 Kb (Figure 2). The 
correlation of clone pV13 expression with metastatic capacity was further studied by 
means of Northern blot analysis of all passages of the rat progression model (Figure 3). 
The RBT 157 line, with the moderate metastatic capacity, shows an higher expression 
level compared to the RBT 323 line, with the high metastatic capacity. The right panel 
of figure 3 illustrates that the higher expression is retained in all the passages of RBT 
157. The other clones did not retain a significant differential expression on further 
evaluation or appeared to originate from ribosomal RNA. 
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Figure 3. Correlation of clone pV13 with metastatic phenotype. 10 /yg of total RNA was 
glyoxylated, size fractionated on 1 % agarose gels and transferred to Hybond-N + nylon 
membranes. The probe was made, using the isolated insert of cDNA clone pV13, by 
random labeling reaction 
DNA sequence analysis of pV13 
To obtain further information on the cDNA clone, the nucleotide sequences were 
determined using the Sequenase Version 2.0 sequence system. Computer-assisted 
comparison of the resulting nucleotide sequences with the EMBL and Gen bank 
nucleotide sequence databases revealed that pV13 is highly homologous to the Rat 
Ferritin Heavy chain gene (97%) (151) and the Mouse Ferritin Heavy chain (94%) 
(217). 
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Discussion 
In search of new molecular markers with predictive value for the progression of 
superficial TCC, we compared two different tumor lines of a rat TCC model system at 
the level of gene expression using differential hybridization analysis We observed an 
overexpression of ferritin H m the RBT 157 tumor line which displays the lowest 
metastatic capacity and the best differentiated phenotype 
Ferritin H combines with the ferritin L subunit to form the iron storage protein ferritin 
(143) Ferritin H-nch molecules take up and release iron more readily than L-nch 
molecules, that are more suited for long-term storage (150) A relationship between 
ferritin and cancer has been proposed, since serum ferritin is frequently elevated m 
patients with cancer (48,246) Some neoplastic cells also exhibit a remarkably altered 
ferritin subunit composition (ι e enrichment for the heavy chain subunit) as compared to 
their normal counterparts (24,232) A direct association between oncogenic 
transformation and ferritin synthesis has been suggested, since the adenovirus EIA 
oncogene specifically represses ferritin H expression (223) The observed 
downregulation of ferritin H expression in the more malignant tumor line RBT 323 is in 
concordance with this observation The correlation between ferritin H expression and a 
number of differentiation processes shown by others (9,27), is corroborated in this study 
by the overexpression of ferritin H in the better differentiated tumor line RBT 157 In 
smooth muscle cells it is proposed that cAMP promotes ferritin H expression resulting in 
both growth arrest and an enhanced differentiated phenotype (123) 
The exact biological consequences of altered ferritin subunit composition are not well 
understood It may result in modulation of the iron binding capacity of ferritin and 
ultimately, the regulatory pools of free iron (143,222) An enrichment for the ferritin H 
subunit leads to more efficient iron detoxification and cellular protection against free 
radical formation (179) 
It should be emphasized that the mechanisms underlying the altered subunit composition 
of ferritin in neoplastic cells are not elucidated Ferritin H is located on chromosome 11 
(86), near 1 lql3 (67), a region that is sometimes amplified in bladder cancer (171) We 
have determined that the ferritin H gene is not within the amphcon on l lq l3 (data not 
shown) 
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We are currently investigating the value of this differential expression of ferritin H as a 
prognostic marker in human bladder cancer using quantitative comparative Polymerase 
Chain Reaction. 
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Chapter 7 
Summary and general discussion 
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Summary and general discussion 
A significant problem in the clinical management of transitional cell carcinoma of the 
bladder (TCC) is the identification of those patients that are at risk for progression of 
their disease. In addition to the "classic" histopathologic diagnosis and clinical 
parameters, new markers identifying patients at risk for tumor progression are urgently 
needed. The advances in the molecular approach to tumor biology of the last years 
resulted in a better understanding of cancer genetics and new potential prognostic 
markers. This thesis describes two approaches to evaluate molecular prognostic markers: 
(i) the major part focuses on the prognostic value of the known tumor suppressor gene 
p53 and its significance as a diagnostic tool, (ii) the use of differential hybridization 
analysis as a method to identify new molecular prognostic factors. 
Alterations of p53 can be identified directly at the genetic level, by detecting mutations 
in the p53 gene using Polymerase Chain Reaction-Single Strand Conformation 
Polymorphism (PCR-SSCP) analysis or indirectly by the detection of p53 protein 
overexpression using immunohistochemistry (IHC). These two methods were compared 
in chapter 2 to assess their reliability. Although a good concordance (p<0.02) between 
p53 mutation by SSCP analysis and p53 overexpression by IHC was observed, in a 
substantial number of tumors discrepancies were found. Two out of eight tumors with a 
SSCP proven p53 mutation showed no p53 immunoreactivity at all, most likely as a 
result of loss of the nuclear localization signal. In addition to these "false negatives", p53 
overexpression was observed in 23% of the tumors without any sign of p53 mutation as 
assessed by SSCP analysis. Therefore, despite the tight correlation between p53 
mutation and p53 overexpression, there is no direct causal relationship between mutation 
and overexpression. Apparently other events than mutation can trigger p53 stability. 
Additional research is necessary to characterize these events and to understand the 
mechanisms through which this overexpression without a concomitant mutation reflects 
alteration of p53 function and consequently gives rise to an altered phenotype in cancer 
cells. 
Clinical parameters were compared with p53 overexpression (IHC) and p53 mutation 
(PCR-SSCP) (Chapter 2 and 3). A significant correlation between p53 alteration and 
grade as well as stage was observed (p<0.05 vs. IHC and pO.001 vs. SSCP, 
respectively). Moreover, p53 alteration is an unfavorable prognostic factor for the whole 
group of bladder cancer patients (p<0.01 vs. IHC and pO.001 vs. SSCP, respectively). 
No association between p53 alteration and decreased survival was found for invasive 
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tumors. The immunohistochemical results for invasive TCC are in contrast with other 
studies. Differences in treatment of patients, antibody, methodology and scoring systems 
used might explain these differences. However, a recent study has shown that p53 
overexpression is a significant predictor of tumor progression for the group of muscle-
invasive tumors, only when the disease is confined to the bladder (pT<3a). With more 
extensive disease (pT>3b), p53 overexpression has no additional prognostic value. 
Because of the relatively small number of invasive tumors in our study, we could not 
compare these two groups. In superficial TCC a trend was observed towards poorer 
survival for the patients showing p53 overexpression. No p53 mutations were observed 
in this group of superficial tumors. This difference stresses again the discordance of p53 
immunohistochemistry and p53 mutation analysis. 
In chapter 3 also the association between p53 mutations and frequency of allelic loss, as 
a putative indicator of genetic instability, was investigated. A high frequency of allelic 
loss was found in tumors with a p53 mutation, suggesting a correlation with genetic 
instability, which could be explained by an altered Gl-S cell cycle checkpoint, resulting 
from the loss of wild type p53 function. 
It is critically important to define if, and when p53 mutations occur during tumor 
progression from superficial (Ta) tumors to lamina propria invasive (Tl) tumors and 
muscle invasive (T2-T4) tumors. To assess the value of p53 mutations in predicting the 
progression of superficial TCC, consecutive bladder washings from high risk superficial 
TCC patients (indicated by quantitative karyometric analysis) were examined (Chapter 
4). We chose for direct analysis of mutations because of the more objective nature of 
this method compared to IHC. Bladder washings have the advantage over histological 
biopsies in that they reflect the general status of the bladder mucosa since cells from the 
entire bladder are sampled. Moreover, this is a simple outpatient procedure and patients 
can be monitored more frequently. Six out of 13 patients that clinically progressed (to 
pT>2) showed a p53 mutation in one or more of their bladder washings prior to 
progression. In the control group (no progression) only one out of 13 patients showed a 
p53 mutation. In high risk patients, as indicated by quantitative karyometric analysis, the 
occurrence of a p53 mutation has a positive predictive value for progression to invasive 
disease of 86%. The low negative predictive value (63%) implicates that, although a p53 
mutation indicates a malignant potential for the tumor, the absence of a p53 mutation 
does not guarantee a good prognosis. Since p53 mutations were found in samples prior 
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to documented progression their presence could identify patients who need a change in 
their treatment strategy to potentially prevent progression to invasive disease. The 
clinical usefulness of p53 mutation analysis as a diagnostic tool should now be assessed 
in a large prospective study. 
Chapter 5 describes the comparative p53 mutation analysis of bladder washings and 
their synchronous tumors to determine the actual value of bladder washings to assess the 
p53 status of the histological specimens. A significant correlation between the p53 status 
of bladder washings and histological specimens was observed if these were compared 
among the specimens of a single patient (p<0.05). Overall, in two patients (2 out of 15) 
the mutation present in the tumors was not detected in the bladder washings and in one 
additional patient the mutation in the bladder washing was not detected in the 
histological specimens. These conflicting results between bladder washings and 
histological specimens could partly be explained by the architecture of the tumors. This 
study shows that the analysis of p53 mutations in consecutive bladder washings of a 
patient does generally reflect the p53 status of the synchronous tumors. As addressed 
earlier, washing of the bladder is a simple outpatient procedure, whereby monitoring of 
patients on more frequent basis is possible. This could lead to an increased detection of 
TCC patients at high risk for progression and thereby potentially prevent this 
progression to invasive disease. 
In addition to the study of the prognostic value of the known tumor suppressor gene p53, 
we used differential hybridization analysis to identify new molecular markers that are 
associated with the progression of superficial bladder cancer (Chapter 6). Primary 
tumor material is usually composed of subpopulations with different malignant potential 
and is therefore not suitable to identify TCC progression markers. In this study a rat 
bladder tumor model system was used, that phenotypically and cytogenetically 
resembles human superficial TCC. The mRNA populations of low and high metastatic 
tumor lines were compared. Ferritin Heavy (H) chain was identified to be overexpressed 
in the tumor line with lowest metastatic capacity and a more differentiated phenotype. 
Ferritin H combines with the ferritin light subunit to form the iron storage protein 
ferritin. A relationship between ferritin and cancer has been proposed and some 
neoplastic cells exhibit a remarkably altered ferritin subunit composition compared to 
their normal counterparts. The overexpression of ferritin H in the more differentiated 
tumor line is a corroboration of the observed association between ferritin H and a 
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number of differentiation processes. The observed lower expression of ferritin H in the 
more malignant tumor line is in concordance with the observation that during oncogenic 
transformation, the adenovirus EIA oncogene specifically represses ferritin H 
expression. Since we used a rat bladder tumor model system for the differential 
hybridization experiments, the value of the differential expression of ferritin H as a 
prognostic marker in the human system remains to be elucidated. 
The studies described in this thesis emphasize that alterations in the tumor suppressor 
gene p53 are important in the clinical behavior of bladder tumors. Although a good 
overall concordance between p53 gene mutation and p53 protein overexpression in 
relation with grade, stage and survival exists, there is no direct causal relationship 
between mutation and protein overexpression. In the group of high risk superficial TCC 
patients, identified by quantitative karyometric analysis, the occurrence of a p53 
mutation as examined in bladder washings, appears to be of value as an additional 
marker to predict progression to invasive disease. In spite of these promising results, it is 
obvious that more prognostic markers are needed to increase not only the positive 
predictive value, but especially the negative predictive value of this screening procedure. 
The technique of differential display could be useful as a tool to identify new prognostic 
markers, provided that the compared mRNA populations are very precisely defined. 
Good candidates for the panel of prognostic markers that are available at this moment, 
are Epidermal Growth Factor Receptor and E-cadherin. Together with the "classic" 
histopathologic diagnosis and clinical parameters this panel of prognostic markers 
should be evaluated in a large prospective study, with well defined patient populations 
and standardized technical procedures to assess their exact clinical relevance. 
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Samenvatting en algemene discussie 
Een belangrijk probleem bij de klinische behandeling van transitioned cel carcinoma 
van de blaas (TCC), is de identificatie van patiënten met een risico voor progressie van 
hun ziekte Naast de "klassieke" histopathologische diagnose en klinische parameters is 
er dringend behoefte aan nieuwe markers, die patiënten met een risico voor 
tumorprogressie kunnen identificeren De laatste jaren heeft de vooruitgang in de 
moleculaire benadering van tumorbiologie geresulteerd in een beter begrip van 
kankergenetica en nieuwe potentiële prognostische markers Dit proefschrift beschrijft 
twee benaderingen om moleculaire prognostische factoren te evalueren (1) de 
prognostische waarde van het bekende tumorsuppressor gen p53 en zijn belang als 
diagnostisch hulpmiddel, (u) het gebruik van de differentiële hybridisatie analyse als een 
methode om nieuwe moleculaire prognostische factoren te identificeren 
Op genetisch nivo kunnen p53 veranderingen direct geïdentificeerd worden door 
mutaties in het p53 gen te detecteren, gebruik makend van de Polymerase Chain 
Reaction-Single Strand Conformation Polymorphism (PCR-SSCP) analyse, of indirect 
door detectie van overexpressie van het p53 eiwit, gebruik makend van 
ïmmunohistochemie (IHC) Om hun betrouwbaarheid te bepalen zijn deze twee 
methoden onderling vergeleken in hoofdstuk 2 Ondanks de goede correlatie (p<0 02) 
tussen p53 mutatie, bepaald door SSCP analyse, en p53 overexpressie, bepaald door 
IHC, zijn in een aanzienlijk aantal tumoren verschillen gevonden Twee van de acht 
tumoren met een p53 mutatie (SSCP) vertoonden in het geheel geen p53 
ïmmunoreactiviteit, waarschijnlijk veroorzaakt door verlies van het kern locahsatie 
signaal Naast deze "onjuist negatieven", is p53 overexpressie waargenomen in 23% van 
de tumoren waarbij geen p53 mutatie aangetoond kon worden door SSCP analyse 
Daarom is er, ondanks de sterke correlatie tussen p53 mutatie en p53 overexpressie, 
geen direct causaal verband tussen mutatie en overexpressie Blijkbaar kunnen behalve 
mutaties ook andere gebeurtenissen stabiliteit van p53 veroorzaken Aanvullend 
onderzoek is nodig om deze gebeurtenissen te karakteriseren en de mechanismen te 
begrijpen waardoor deze overexpressie, zonder een gelijktijdige mutatie, verandering 
van p53 functie weerspiegelt en vervolgens een ander phenotype veroorzaakt in 
kankercellen 
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Klinische parameters zijn vergeleken met p53 overexpressie (IHC) en p53 mutatie 
(PCR-SSCP) (Hoofdstuk 2 en 3). Een significante correlatie tussen p53 verandering en 
zowel graad als stadium is waargenomen (p<0.05 vs IHC en p<0.001 vs SSCP, 
respectievelijk). Bovendien is p53 verandering een slechte prognostische factor voor de 
hele groep van blaaskanker patiënten (pO.Ol vs IHC en pO.001 vs SSCP, 
respectievelijk). Voor invasieve tumoren is er geen associatie gevonden tussen p53 
verandering en een verkorte overlevingsperiode. De immunohistochemische resultaten 
voor invasieve tumoren zijn in tegenspraak met andere studies. Verschillen in de 
behandeling van patiënten, het antilichaam, methode en scoringssysteem dat gebruikt is, 
zouden deze discrepanties kunnen verklaren. Echter, een recente studie heeft laten zien 
dat voor de groep van spier-invasieve tumoren, p53 overexpressie slechts significant 
tumorprogressie voorspelt, wanneer de ziekte zich beperkt tot de blaas (pT<3a). Indien 
de ziekte meer uitgebreid is (pT>3b), heeft p53 overexpressie geen additionele 
prognostische waarde. Vanwege het relatief kleine aantal invasieve tumoren in onze 
studie hebben we deze twee groepen niet kunnen vergelijken. In oppervlakkig TCC is er 
een verschuiving waargenomen naar een kortere overlevingsperiode voor de patiënten 
met p53 overexpressie. Er zijn geen p53 mutaties waargenomen in deze groep van 
oppervlakkige tumoren. Dit verschil benadrukt opnieuw het onderscheid tussen p53 
immunohistochemie en p53 mutatie analyse. 
In hoofdstuk 3 is ook de associatie tussen p53 mutaties en frequentie van allelisch 
verlies, als een mogelijke indicator voor genetische instabiliteit, onderzocht. Er is een 
hoge frequentie van allelisch verlies gevonden in tumoren met een p53 mutatie, hetgeen 
wijst op een correlatie met genetische instabiliteit. Dit kan worden verklaard door een 
veranderd Gl-S cel cyclus controlepunt, als gevolg van het verlies van de wild type p53 
functie. 
Het is zeer belangrijk om te definiëren of en wanneer p53 mutaties optreden tijdens 
tumorprogressie van oppervlakkige (Ta) tumoren naar lamina propria invasieve (Tl) 
tumoren en spier-invasieve (T2-T4) tumoren. Om de waarde van p53 mutaties te 
bepalen voor het voorspellen van progressie van oppervlakkig TCC zijn opeenvolgende 
blaasspoelingen van oppervlakkige TCC patiënten met een hoog risico (geïdentificeerd 
door kwantitatieve karyometrische analyse) onderzocht (Hoofdstuk 4). We hebben 
gekozen voor directe analyse van mutaties vanwege het meer objectieve karakter van 
deze methode vergeleken met IHC. Omdat cellen van de gehele blaas worden geoogst, 
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hebben blaasspoelingen het voordeel ten opzichte van histologische biopsies dat ze de 
algemene status van de blaas mucosa weergeven. Bovendien is dit een eenvoudige 
poliklinische procedure zodat patiënten vaker kunnen worden gecontroleerd. Zes van de 
13 patiënten met klinische progressie (naar pT>2) vertoonden een p53 mutatie in één of 
meer van hun blaasspoelingen voordat progressie optrad. In de controle groep (geen 
progressie) vertoonde maar één van de 13 patiënten een p53 mutatie. In patiënten met 
een hoog risico, geïdentificeerd door kwantitieve karyometrische analyse, heeft het 
verschijnen van een p53 mutatie een positief voorspellende waarde voor progressie naar 
invasieve ziekte van 86%. De lage negatief voorspellende waarde (63%) impliceert dat, 
ondanks het feit dat een p53 mutatie de kwaardaardige potentie van een tumor aangeeft, 
de afwezigheid van een p53 mutatie geen garantie is voor een goede prognose. Omdat 
p53 mutaties zijn gevonden in samples voor gedocumenteerde progressie, kan hun 
aanwezigheid patiënten identificeren die een verandering in hun behandeling nodig 
hebben om mogelijk progressie naar invasieve ziekte te voorkomen. De klinische 
bruikbaarheid van p53 mutatie analyse als diagnostisch hulpmiddel zal nu bepaald 
moeten worden in een grote prospectieve studie. 
Hoofdstuk 5 beschrijft de vergelijkende p53 mutatie analyse van blaasspoelingen en 
hun vergezellende tumoren om de werkelijke waarde van blaasspoelingen te bepalen 
voor het weergeven van de p53 status van het histologische materiaal. De p53 status van 
de blaasspoelingen en het histologische materiaal vertonen een significante correlatie, 
wanneer deze vergeleken werden voor alle samples van een enkele patient (p<0.05, 
Fischer exact test, two tail). Samenvattend, in twee patiënten (2 van de 15) is de mutatie 
die aanwezig was in de tumoren niet gedetecteerd in de blaasspoelingen. In een derde 
patient is de mutatie in de blaasspoeling niet gedetecteerd in het histologische materiaal. 
Dit tegenstrijdige resultaat tussen de p53 status van de blaasspoelingen en het 
histologisch materiaal kan gedeeltelijk worden verklaard door de architectuur van de 
tumoren. Deze studie laat zien dat de analyse van p53 mutaties in opeenvolgende 
blaasspoelingen van een patient in het algemeen de p53 status van de vergezellende 
tumor weergeeft. Zoals reeds vermeld is het wassen van de blaas een eenvoudige 
poliklinische procedure waardoor controle van patiënten op een meer frequente basis 
mogelijk is. Dit zou kunnen leiden tot een verhoogde detectie van TCC patiënten met 
een hoog risico voor progressie waardoor mogelijk deze progressie naar invasieve ziekte 
voorkomen zou kunnen worden. 
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Naast de studie van de prognostische waarde van het bekende tumorsuppressor gen p53, 
hebben we gebruik gemaakt van differentiële hybridisatie analyse om nieuwe 
moleculaire prognostische markers te identificeren die geassocieerd zijn met progressie 
van oppervlakkig blaaskanker (Hoofdstuk 6). Primair tumormateriaal is meestal 
samengesteld uit subpopulaties met verschillende kwaadaardige potentie en is daarom 
niet geschikt om TCC progressie markers te identificeren. In deze studie is een rat blaas 
tumor model systeem gebruikt, dat phenotypisch en cytogenetisch lijkt op humaan 
oppervlakkig TCC. De mRNA populaties van laag en hoog metastaserende lijnen zijn 
vergeleken. Er is overexpressie van ferritine Heavy (H) chain waargenomen in de 
tumorlijn met de laagst metastaserende capaciteit en beter gedifferentieerd phenotype. 
Ferritine H vormt samen met de ferritine Light subunit het eiwit ferritine, dat zorgt voor 
de opslag van ijzer. Er is een relatie tussen ferritine en kanker voorgesteld en sommige 
neoplastische cellen vertonen een opmerkelijk veranderde samenstelling in ferritine 
subunits, vergeleken met hun normale tegenhangers. De overexpressie van ferritine H in 
de beter gedifferentieerde tumorlijn is een bevestiging van de waargenomen associatie 
tussen ferritine H en een aantal differentiatie processen. De waargenomen lagere 
expressie van ferritine H in de meer kwaardaardige tumorlijn stemt overeen met de 
waarneming dat tijdens oncogene transformatie, het adenovirus EIA oncogen specifiek 
de expressie van ferritine H remt. Omdat we gebruik hebben gemaakt van een rat blaas 
tumor model systeem voor de differentiële hybridisatie experimenten, zal de waarde van 
de differentiële expressie van ferritine H als een prognostische marker in het humane 
systeem nog opgehelderd moeten worden. 
De studies die in dit proefschift beschreven zijn, benadrukken dat veranderingen in het 
tumorsuppressor gen p53 belangrijk zijn voor het klinische gedrag van blaastumoren. 
Ondanks de goede overall overeenkomst tussen p53 gen mutatie en p53 eiwit 
overexpressie in relatie tot graad, stadium en overlevingsperiode, is er geen causaal 
verband tussen mutatie en overexpressie. In de groep van oppervlakkig TCC patiënten 
met een hoog risico, geïdentificeerd door middel van kwantitatieve karyometrische 
analyse, lijkt de verschijning van een p53 mutatie geanalyseerd in blaasspoelingen van 
waarde te zijn als een extra marker om progressie naar invasieve ziekte te voorspellen. 
Ondanks deze veelbelovende resultaten is het duidelijk dat er meer prognostische 
markers nodig zijn om niet alleen de positief voorspellende waarde, maar vooral de 
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negatief voorspellende waarde van deze screenings procedure te verhogen. De 
differential display techniek zou bruikbaar kunnen zijn als een middel om nieuwe 
prognostische markers te identificeren, gesteld dat de te vergelijken mRNA populaties 
zeer precies worden gedefinieerd. Voor het panel van prognostische markers zijn op dit 
moment de Epidermal Growth Factor Receptor en E-cadherin goede kandidaten. Samen 
met de "klassieke" histopathologische diagnose en klinische parameters, zou dit panel 
van prognostische markers geëvalueerd moeten worden in een grote prospectieve studie 
met goed gedefinieerde patiënten populaties en gestandaardiseerde technische 
procedures, zodat de precíese klinische relevantie bepaald kan worden. 
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Het Ene is in alles 
alles is in het Ene 
Als je dit beseft 
ben je niet langer bezorgd 
over je tekortkomingen. 
(Hsin Hsrn Ming, oude Chinese Zen-tekst) 

1 

